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ABSTRACT 
Alzheimer’s disease (AD) is a neurodegenerative disorder that dramatically affects 
the cognition of the patients. Its effect on the motor cortex is not clearly established 
despite clinical observations implying some dysfunction at disease onset. From the 
mild stage, AD patients display a motor behavior different from normal, that is,  
restricted movement with slowness, delayed reaction to external stimuli and 
diminished facial expression. This pattern gradually changes as the disease 
progresses; in fact, at the more advanced stages the patients show an increased 
mobility with nervous movements, pacing, akathisia and falls. These observations 
have been the basis of our investigation of the function of the motor cortex through 
transcranial magnetic stimulation (TMS) in a group of AD patients with mild disease. 
Patients were compared to a group of normal individuals in order to find a 
neurophysiological correlate of their altered motor behavior. The experiments were 
performed in two phases, before and after the oral administration of an 
acetylcholinesterase inhibitor (donepezil) taking into consideration the significant 
role of the cholinergic hypothesis in the pathogenesis of AD. The active motor 
threshold (aMT) which reflects cortical excitability and the silent period (SP) which 
reflects cortical inhibition were measured during the TMS experiments. These 
measurements give an overview of the motor control in early AD, from the 
activation of the pyramidal cells in the primary motor area to the temporary 
inhibition of the contraction of the peripheral muscle. An increased aMT was 
observed in the early AD patients representing decreased excitability of the primary 
motor cortex. Also, an increased duration in SP due to its being scattered by multiple 
electromyographic breakthroughs called late excitatory potentials (LEP) was 
measured, representing impaired cortical inhibition. The administration of donepezil 
restored both neurophysiological parameters to normal indicating a key role of the 
cholinergic system in the regulation of the mechanisms which determine motor 
control in early AD. Additional neurophysiological and pharmacological sub 
experiments that we performed completed these observations. Our results 
combined with recent data from the literature argue in favor of a functional 
disturbance in the cholinergic system instead of cholinergic neuronal loss in early AD. 
The recently demonstrated existence of a direct connection between the basal 
forebrain and the primary motor area enable us to present an original physiological 
model explaining our findings. This model gives a complete explanation of the 
changes in the function of the primary motor cortex at the early stages of AD under 
the regulation of the cholinergic system. 
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CHAPTER 1.   
INTRODUCTION 
 
1.1. EPIDEMIOLOGICAL DATA OF ALZHEIMER’S DISEASE  
Alzheimer’s disease (AD) is the most common degenerative disorder of the 
brain and it has an immense societal impact worldwide. The prevalence of AD 
increases with age, being most frequent in individuals older than 60 years [1, 2]. 
Epidemiological data estimates the prevalence of Alzheimer’s disease at 1-4 % in 
people younger than 65. This rapidly increases to 5% - 10% between the ages of 65-
74 years, to 44 % between75-84 and as high as 46-50 % at the age of 85 and older. 
The average duration of the symptoms from diagnosis to death is around 10 years 
within a range of 4 to 16 years. The proportion of women suffering from Alzheimer’s 
disease in the general population is larger than that of men, explained partially by 
the fact that the average life expectancy of women exceeds that of men. No 
significant difference has actually been found between genders in the new cases of 
Alzheimer’s disease emerging every year [3]. 
 
1.2. PREDISPOSING FACTORS 
Predisposing factors of the disease, apart from old age, are familial history, 
traumatic brain injury, common vascular risk factors (hypertension, diabetes, 
elevated homocysteine, and hypercholesterolemia) and depression [1, 2, 6, 7]. 
Educational and socioeconomic status has been thoroughly examined as another 
possible predisposing factor. Most of the studies concluded that low educational 
level increases the incidence of Alzheimer’s disease [8, 9]. The results of the impact 
of the socioeconomic level are not consistent in the various studies [10, 11]. As 
regards the hereditary predisposition of AD, mutations have been described in three 
CHAPTER 1  -   INTRODUCTION 
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genes: the amyloid precursor protein (APP) gene on chromosome 21, the presenilin 
1 (PS1) gene on chromosome 14 and the presenilin 2 (PS2) gene on chromosome 1. 
These mutations result in an autosomal dominant form of the disease beginning at a 
young age, often in the third decade of life. For late onset Alzheimer’s disease, the 
main known genetic risk factor is the presence of the ApoE gene located on 
chromosome 19 which exists in three forms: ApoE ε2, ApoE ε3, and ApoE ε4. The ε4 
polymorphism has been associated with the more typical sporadic and familial forms 
of Alzheimer's disease, usually beginning after age 65. Nevertheless, more than 90% 
of cases of AD are sporadic without any demonstrated genetic factor. 
 
1.3. PATHOPHYSIOLOGY 
Regarding pathophysiology, the hallmarks of the disease are senile neuritic 
plaques and neurofibrillary tangles [1, 2, 3]. Senile neuritic plaques are spherical 
lesions of amorphous material surrounded by enlarged axonal endings (neurites). 
The main protein found in the core of these lesions is a β-peptide, amyloid (Αβ), 
which is derived from a transmembrane protein, the amyloid precursor protein 
(APP) by proteolysis through α,β and γ-secretase. Amyloid is also found scattered 
throughout the cerebral cortex in a “diffuse” form and additionally is detected in the 
walls of small blood vessels near the plaques (argyrophilic angiopathy). 
Neurofibrillary tangles are fibrillary intracytoplasmic structures within the neurons. 
These structures are made of a hyperphosphorylated form of the microtubular 
protein “tau” and appear as pairs of helicoidal filaments (Figure 1.)   
 
 
 
 
 
 
 
 
Figure 1: pathological hallmarks of AD: plaques and tangles  
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Biochemically, the abnormality which is most prevalent in a brain affected by 
AD pathology is the significant reduction of the activity of the enzyme choline 
acetyltransferase (ChAT). This enzyme is responsible for the biosynthesis of the 
neurotransmitter acetylcholine and is found in cholinergic neurons. The vast 
majority of the cholinergic innervation of the human brain originate in the basal 
forebrain (medial septal nucleus, diagonal band of Broca, nucleus basalis of 
Meynert).There is no general cholinergic deficit in AD but a selective loss loss of the 
cholinergic projection pathway from the deep nuclei in the septum and diagonal 
band of Broca to the hippocampus and from the nucleus basalis of Meynert to the 
cerebral cortex. The cholinergic innervation of the striatum and of thalamus remains 
relatively intact. 
The severity of cognitive loss is roughly proportional to the loss of choline 
acetyltransferase [12, 13, 14]. This observation had been the basis for the 
formulation of the cholinergic hypothesis, a very widely accepted hypothesis for the 
pathogenesis of Alzheimer’s disease. The cholinergic hypothesis links the cognitive 
deficit of the affected individuals to a cholinergic deficit. The therapeutic effect of 
acetylolinesterase inhibitors upon the cognitive functions of the patients affected by 
AD supports the cholinergic hypothesis [15, 16, 17]. However, the pathogenesis of 
the disease cannot be based solely on the cholinergic deficit. It is far more complex, 
including the crucial, though not fully understood, role of amyloid and Tau protein in 
the whole physiopathological process. 
The areas of the brain predominantly affected by the degenerative process 
during the course of Alzheimer’s disease are the associative cortical areas of 
temporal, parietal and frontal lobes and the limbic system. Neuritic plaques and 
neurofibrillary tangles are found from the very early stages in olfactory areas, 
particularly the olfactory bulb which is considered as the area of the brain where the 
degeneration begins in AD. Along with neuronal loss, plaques and tangles 
progressively occupy the hippocampal formation including layer II of the entorhinal 
cortex and also amygdala, cingulate gyrus, nucleus basalis of Meynert and the 
associative temporo-parietal and frontal areas of the neocortex.                        
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Primary visual areas and motor cortex appear to be spared the neurodegenerative 
process [19] (Figure 2.). 
 
 
 
 
 
 
 
 
Figure 2: progression of pathological hallmarks of AD during the course of the 
disease 
 
1.4. CLINICAL CHARACTERISTICS 
The clinical manifestations of AD evolve from the earliest signs of impaired 
episodic memory to severe cognitive impairment [4, 20]. The course of the disease is 
progressive leading to complete incapacity and death. In the early stages of the 
disease, the most commonly referred symptom is impaired episodic memory, 
meaning memory deficit for newly acquired information, whereas memory for 
remote events is relatively well preserved.  As the disease progresses, other 
cognitive functions besides memory are seriously affected, such as language, both 
oral and written, abstract reasoning, ability for sound judgment and executive 
function. Along with the degeneration of certain areas of the brain, the classical triad 
of apraxia–aphasia-agnosia is finally established. In the more progressed stages 
other symptoms commonly exhibited are sleep disturbances, delusions, visual and 
auditory hallucinations, agitation and sometimes psychotic events. Depression and 
anorexia occur in 5% to 8% of patients regardless of the severity of the disease. 
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CHAPTER 2.   
BACKGROUND OF THE STUDY 
 
2.1. MOTOR BEHAVIOUR IN ALZHEIMER’S DISEASE  
Given that the primary motor cortex is supposed to be spared the 
neurodegenerative process, one would assume that no motor abnormalities would 
be expected in the clinical picture of AD patients. Besides, disturbances in motor 
function of these patients rarely if ever are included in the standard symptomatology 
of the disease which focuses mainly on the cognitive and behavioural dysfunction.  
However, in everyday clinical practice it is evident that the motor behaviour of the 
patients who suffer from Alzheimer’s disease differs in comparison with normal 
individuals of the same age. Balance and gait are affected with a positive correlation 
to the stage of the disease [21, 22]. Falls are much more common in AD patients [23, 
24] and focal motor signs not attributed to a specific lesion can also be detected in 
these patients [25]. Some studies based on animal models [26, 27,28, 29] provide 
experimental evidence, contrary to what was traditionally believed, which supports 
the clinical observations concerning the involvement of the motor system in the 
course of Alzheimer’s disease. 
It may be observed that often patients in advanced stages of Alzheimer’s 
disease exhibit some kind of hyperkinesia. Their muscle tone may be increased, they 
pace and wander without specific purpose, they exhibit a lot of stereotypical 
behaviours, they engage in searching behaviour and they are rarely able to relax, 
often giving a picture of akathisia. This kind of motor behaviour, when evaluated as 
an isolated element distinct from the cognitive deficit, could be safely viewed as 
disinhibited normal motor behaviour. A possible explanation for this hyperkinetic 
state could be some lack of inhibition of the motor cortex. In Alzheimer’s disease 
CHAPTER 2  - BACKGROUND OF THE STUDY 
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besides the neurodegenerative process (plaques and tangles) detected in the 
associative cortex and the limbic system, there is also a serious disturbance or a 
complete loss of the neuronal connections from the frontal, temporal and parietal 
areas to the primary motor cortex .These areas of the brain schedule, prepare and 
continually regulate the motor functions whereas the motor cortex is responsible for 
finally implementing the movement. Nevertheless, it is not clear from currently 
available studies [30, 31] whether the alteration of motor function observed in 
progressed AD represents a primary or a secondary defect of the primary motor 
area. It is questionable whether the changes in the motor behaviour of progressed 
AD patients are due to a secondary infliction of the neurodegeneration of the 
affected areas of the brain and their associated neural connections on the motor 
cortex, or whether they are caused by a primary dysfunction of the motor cortex 
itself.    
Regarding changes in motor behaviour during the course of AD, specific 
mention has to be made about the extrapyramidal features which are displayed, to a 
certain degree, by some AD patients. These features show great variability. Scarmeas 
et al [32] evaluated the motor signs of extrapyramidal origin exhibited by the 
patients during the course of AD. In this study, the clinical motor features examined 
in a large group of patients followed for 13 years were; speech, facial expression, 
posture and bradykinesia/ hypokinesia. It was found that as the disease progressed, 
the prevalence and severity of the abnormal motor signs increased accordingly, 
reaching 71% in the last year of the study. In that study patients were selected with 
great care so as to exclude, as far as possible, Lewy body pathology comorbitidy 
which could have caused misinterpretation of the results or scientific bias. The 
investigators attributed their results to extranigral lesions which involved 
mesocortical dopaminergic pathways, loss of striatal dopaminergic transporter sites 
and reduced dopaminergic D2 receptors in the putamen. An alternative explanation 
was that the dopaminergic system may have been involved but through AD and not 
Lewy body pathology given that senile plaques were reported in the putamen, 
caudate nucleus and substantia nigra [33] and neurofibrillary tangles were noted in 
substantia nigra [34].  
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An increased awareness of Alzheimer’s disease over the last 20 years, has led 
more patients to seek expert advice while still in the initial stages of the disease.   
Apart from altered cognition it has been clinically observed that early AD patients 
more often exhibit a type of motor behaviour different from the usual hyperkinesia 
of advanced AD. The patients in the early stages of the disease appear less reactive 
to external stimuli. The initiation of a motor reaction and also the velocity of the 
execution of a certain movement take longer when compared to normal individuals 
[35]. These patients often exhibit diminished facial expression but not in the form of 
the usual extrapyramidal hypomimia.  They display a narrow range of movement of 
the facial muscles responsible for expressing emotion and alertness of the perceived 
external environment often presented as apathy. Their whole motor function from 
their ability to react fast when in their baseline calm state [36] to performing a 
simple or complex movement [37] and walking [38] is slower, exhibiting a form of 
hypokinesia. 
A recent study of Vidoni et al. [39] supports the clinical observations of 
impaired motor function in early AD patients from a neuroradiological point of view. 
The authors examined a group of early-stage AD patients using functional MRI while 
they were performing a visually-directed, simple motor task and compared them to 
a group of normal individuals in order to investigate AD-related differences in 
regional brain activation during motor performance. The results of this study have  
shown that the early AD patients displayed increased co-activation of bilateral motor 
and visual regions of the cerebral cortex. These findings could either represent 
inefficiency in the motor network as a consequence of the disease or could be 
interpreted as compensatory activation.  Nevertheless, they provide further 
evidence that in the early stages of AD, motor function is altered even during simple 
motor tasks, suggesting an impaired connectivity between the primary motor area 
(M1) and other areas of the brain. The results of this recent study are in accordance 
with an older study by Agosta et al [40] who used fMRI to examine possible changes 
in the sensory and motor cortex of AD patients. They actually identified functional 
changes in areas of the brain traditionally considered to be spared in early AD, in a 
form of an initial phase of hyperactivation of the sensorimotor cortex in patients 
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suffering from amnestic mild cognitive impairment, followed by a phase of 
hypoactivation of this area in AD patients. 
 
2.2. THE MOTOR BEHAVIOUR OF AD PATIENTS THROUGH THE MODEL 
OF BROWN AND PLUCK 
A publication of Brown and Pluck [41] about the pathology of motivation and 
goal-directed behaviour in neuropsychiatric disorders which display ‘negative’ 
symptoms, including Alzheimer’s disease, provides some original ideas which could 
be used to explain the pathophysiology of the motor behaviour of AD patients. The 
authors propose that goal-directed behaviour and the details of its execution can be 
theorized as a reflection of cognitive and motor function in close interaction. It is 
proposed that preparation, initiation and termination of a goal–directed movement 
requires active co-operation between the anatomical areas of the limbic system 
(amygdala, hippocampus) and those of the striato-thalamo-cortical circuit in the 
form of a functional network in order to first inspire, then schedule, prepare and 
finally execute the movement. This complete procedure initially involves the 
affective areas of the brain (limbic system), then the cognitive areas (prefrontal 
cortex, cingulated gyrus) and finally the motor areas (striatum – premotor, motor 
cortex). The interaction between those brain circuits is constantly dynamic in order 
to achieve a certain goal which could be a simple or complex movement or a series 
of expressions and motor reactions. Given that the motor cortex is the final area of 
the brain responsible for the execution of movement we can assume that any 
divergence from the normal motor behaviour observed in AD patients could lead to 
an altered functioning of their motor cortex. The degree to which the possible 
changes in the function of motor cortex alters the motor behaviour of AD patients is 
determined by the existing direct or indirect connections between the various areas 
of the brain involved in the goal-directed movement and their anatomical and 
functional connection to the primary motor cortex.  
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A schematic presentation of the model proposed by Brown and Pluck 
demonstrating the interactions among various areas of the brain is displayed in the 
Figure. 3. 
 
 
The significant alterations in normal motor behaviour which are already 
present from the disease’s onset in patients suffering from AD, if viewed through the 
aforementioned model of Brown and Pluck, outline an important early effect of 
Alzheimer‘s disease upon the function of the primary motor cortex.  The 
pathophysiology of this effect is probably very distinct and not connected to or 
dependent on the usual neuropathological findings traced in certain areas of the 
Fig 3. 
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brain as in early AD there is no evident neuronal loss in the primary motor cortex. At 
this stage the neuropathological abnormalities are limited to the limbic areas and 
the hippocampus [19].  A new pathophysiological explanation must be given for the 
changes in motor behaviour of early AD patients given that the motor cortex is not 
affected by amyloid plaques, neurofibrillary tangles and neuronal loss early in the 
course of the disease.   
 
2.3. TRANSCRANIAL MAGNETIC STIMULATION ON THE STUDY OF 
MOTOR CONTROL IN AD 
An efficacious way to explore changes in motor control and motor behaviour 
in Alzheimer disease is through neurophysiological studies. Transcranial magnetic 
stimulation (TMS) is a neurophysiological tool which is easily accessible, painless, 
safe, not costly, simple in its application and gives fast results when used on 
individuals. The stimulator produces an electromagnetic induction that generates 
electric currents using a rapidly changing magnetic field. An electromagnetic coil is 
held close to the skull of the individual tested and short electromagnetic pulses are 
delivered through the coil. The magnetic pulse passes unattenuated through the 
scalp and skull, and induces small electrical currents stimulating the neurons of the 
targeted area of the brain [42]. In this way, TMS can activate cortical motor areas 
and the corticospinal tract giving valuable information about the motor excitability in 
the central nervous system. A very important factor is that the whole procedure 
causes only minimal discomfort to the subject.  
TMS activates the pyramidal cells of the primary motor area (M1) and 
following the corticospinal tract the electric current activates the alpha motor 
neurons in the spinal level causing contractions in contralateral body muscles. This 
results in a motor evoked potential (MEP) -compound muscle potential (CMAP) in 
the activated muscle, which is recorded by a conventional electromyography device. 
The most commonly used muscles from which CMAPs are recorded during TMS are 
the small muscles of the hand: first dorsal interosseous (FDI), abductor pollicis brevis 
(APB) and abductor digiti minimi (ADM) [43].  
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Different types of coils and stimulators can be used to perform TMS. A 
detailed description exceeds the purpose of this work; though it can be found in 
certain textbooks specializing in TMS [44, 45]. The evaluation of motor function in 
the central nervous system by TMS is achieved by the measurement of some 
standard neurophysiological parameters such as the central motor conduction time, 
the motor threshold and the silent period. Another parameter often measured is 
Short-latency afferent inhibition (SAI). Central Motor Conduction Time (CMCT) is 
defined as the time from the motor cortex to the spinal motor neurons [44]. Motor 
threshold (MT) is defined as the minimal stimulus intensity that produces a motor 
evoked potential (MEP) greater than 100 μV in 5 out of 10 trials in muscle [45]. It is 
called resting (rMT) or active (aMT) motor threshold dependent on whether the 
tested muscle is at rest or at an isometric contraction during TMS. Silent period (SP) 
is defined as the duration of interruption of electromyographic activity of a 
moderately tonically active muscle (40- 50% of maximum contraction) when the 
contralateral motor cortex is stimulated by TMS intensities of 110%–160% of motor 
threshold [46]. Short-Latency Afferent Inhibition (SAI) refers to the suppression of 
the amplitude of a MEP produced by a conditioning afferent electrical stimulus 
applied at the median nerve at the wrist approximately 20 ms prior to TMS of the 
hand area of the contralateral motor cortex [47]. 
 
2.3.1. Previous TMS studies on Alzheimer’s disease. 
Various studies have assessed the excitability of the motor cortex in 
Alzheimer’s disease by calculating the motor threshold and silent period, in other 
words, the TMS parameters that more directly reflect cortical excitability and cortical 
inhibition respectively. Systematic research in this field was started in the 90’s by 
Perretti et al. [48]. Their results pointed towards an increased resting motor 
threshold in the patient group, demonstrative of decreased cortical excitability in 
AD. De Carvalho et al. [49] in 1996 presented different results to those of Perreti et 
al. showing a decrease instead of increase in motor threshold of the patient group.  
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Pepin et al. [50] in their study in 1999 found that both TMS parameters were 
significantly reduced in AD patients when compared to normal individuals leading to 
the conclusion that there is an increased excitability of motor cortex in Alzheimer’s 
disease. Similar results to the study of Pepin et al. in terms of motor threshold can 
be seen in the study by Pennisi et al.  [51] in 2002 and the study of Ferreri et al. [52] 
in 2003. 
However, in the study performed by Nardone et al. [53] in 2008 both rest and 
active motor threshold were found to be increased in the group of AD patients 
compared to controls, even though this increase did not reach statistical significance. 
Apart from motor threshold, short latency afferent inhibition (SAI) was also 
examined as an indicator of the function of the cholinergic pathways in the motor 
cortex. The amount of SAI was significantly smaller in early AD patients than in 
controls leading to the conclusion that a central cholinergic dysfunction occurs in the 
earlier stages of AD. The results of Nardone et al. were in accordance with those of 
older studies conducted by Di Lazzaro et al. [54, 55, 56,57]. The latter explored the 
excitatory and inhibitory neuronal pathways that control the motor cortex function 
in AD patients and the role of the cholinergic system by performing their 
experiments under pharmacological manipulation with an acetylcholinesterase 
inhibitor.  
More recently, Khedr et al. [58] in 2011 conducted a TMS study in AD 
patients categorizing them by the stage of the disease and evaluating the motor 
threshold and silent period.  A significant positive correlation was noted between 
the rest and active motor threshold and disease progression as rMT and aMT were 
both increased in mild dementia and significantly decreased in advanced AD 
compared to normal subjects.  The correlation with the evolution of the disease was 
negative for the silent period. Given these particular results, the investigators 
assumed that advanced AD is associated with hyperexcitability of the motor cortex 
and they attributed an important role to certain neurotransmitters as γ-
aminoboutyric acid (GABA) and Glutamate. 
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CHAPTER 3. 
THE STUDY 
It is evident from the previous chapter that the neurophysiological TMS 
studies which have investigated the function of the primary motor cortex in 
Alzheimer disease, give conflicting evidence regarding the excitability of the cortical 
motor areas and the related neuronal pathways that lie beneath them. Some studies 
point towards a general increase in excitability of the motor cortex in AD [49, 50, 51, 
52] while others [48] exhibit the opposite result suggesting a decrease in cortical 
excitability and there are yet others [58], which correlate the excitability of the 
motor cortex to the stage of Alzheimer’s disease. Possible reasons for the variability 
of the results in these studies could be the different methodologies used by different 
investigators, the technical restrictions of each study and also the heterogeneity of 
the participating patients in terms of the progression of the disease.  
Given that Alzheimer’s disease is an evolutionary process, the modifications 
in neuropathology and biochemistry during its course could have a very significant 
effect upon the excitability of the primary motor cortex in each stage of the disease.  
In a previous study where TMS was applied on severely affected patients [48] the 
observed modulation of cortical excitability was attributed to cortical atrophy. It has 
been suggested that cortical atrophy increases the distance between the site of the 
stimulation on the scalp and the TMS activated pyramidal cells of the primary motor 
area leading to an increased motor threshold.  However, this is not the case when 
such TMS studies are performed in patients suffering from mild and moderate 
Alzheimer’s disease. In the early stages no measurable cortical atrophy is evident 
particularly in the motor areas. It is known from the literature [19] that the primary 
motor cortex is free from senile plaques and neurofibrillary tangles in mild AD. 
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 Interestingly enough some experimental paradigms [53, 54, 55, 56, 57,] have 
attributed a regulating role to certain brain neurotransmitters such as acetylcholine, 
GABA and glutamate, upon the motor control of AD patients. However, a clear 
hypothesis about the specific neuronal circuits involved has not been formed. 
 
3.1. THE AIM OF THE STUDY  
Our study was motivated by the clinical observations of altered motor behaviour in 
AD patients at the mild stage of the disease. As cortical atrophy is not implicated, the 
changes in cortical excitability rely probably on dysfunctional neuronal pathways. 
The aim of the study was: 
1. To identify and confirm changes in the function of the motor cortex in 
early AD patients.   
2.  To provide an explanation for these changes revealing the responsible 
pathophysiological mechanisms  
The question that our research was seeking to answer is: “Could some specific 
neuronal pathways which utilize certain brain neurotransmitters be at the root of 
the altered motor behaviour that the AD patients exhibit at the early stage of the 
disease?”  
 
3.2. THE METHODOLOGY 
In order to carry out our study we chose the method of Transcranial 
Magnetic Stimulation (TMS) because of the many advantages it offers, in terms of 
accessibility, safety, validity and convenience for the patient. The prospect of 
comparing our results with previous TMS studies which provided conflicting 
evidence about motor control in AD was indeed challenging.  
Our study consists of three experiments, a main TMS experiment which 
answers our basic research question and two subexperiments to verify and enhance 
the validity of our main experimental body.  
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Considering the importance of the cholinergic hypothesis in the pathogenesis 
of Alzheimer’s disease, we decided to perform our main TMS experiments on a 
group of AD patients at the early stage of the disease. First, we examined them 
before the administration of any treatment and then after treating them with an 
acetylcholinesterase inhibitor (donepezil).  In this way we would be able to observe 
the possible effect that the cholinergic intervention exerts upon the function of 
motor cortex in early AD. More importantly, we would be able to form a hypothesis 
about the underlying neuronal pathways which determine the function of motor 
cortex and affect the motor behaviour of the patients.  
In the subexperiment 1, we examined the effect of another pharmaceutical 
substance (memantine) upon motor cortex applying the same TMS experimental 
procedure in another smaller sample of early AD patients. As memantine acts 
through a different neuronal pathway than the cholinergic one, this subexperiment 
would provide further evidence for the specific role of certain neuronal pathways in 
the regulation of the motor control in Alzheimer’s disease. 
In the subexperiment 2 we examined whether the changes in the function of 
motor cortex displayed at the early stages of AD have a clinical implication in motor 
behaviour. In a group of early AD patients, distinct from the one we had used in our 
main TMS experiment, we examined the motor reaction time after a visual stimulus 
was given to the patients. The experiment was performed before and after treating 
the patients with donepezil and the results were compared with a group of normal 
individuals separate than the one we used for our TMS experiment. 
All our experiments were carried out in CHR Citadelle in Liege.  
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3.3. THE EXPERIMENTS 
An analytical description of the 3 experiments carried out in the study can be 
found below, each followed by a small discussion of the results. 
 
3.3.1. MAIN TMS EXPERIMENT 
A. Patients  
The sample for our study was selected from patients from the outpatient 
memory clinic of the neurological department. It included patients who were 
diagnosed with probable Alzheimer’s disease based on the criteria of the National 
Institute of Neurological and Communicative Disorders and Stroke – Alzheimer’s 
disease and Related Disorders Association. According to the Clinical Dementia Rating 
Scale, they were in the early stage of the disease. The Mini-Mental State 
Examination (MMSE) was performed to all patients. Any patient who exhibited signs 
of other neurological diseases was excluded from the sample. The same exclusion 
was applied to anyone who was under pharmaceutical therapy with medications 
which could have a possible impact on cognitive function or could in any way affect 
the excitability of the nervous system.  
We finally recruited thirteen (13) patients, six (6) men and seven (7) women. 
Their median age was 75 years (with limit ages 54-83 y) and they were all right-
handed. For all the recruited patients the neurological examination of the motor 
system was normal. Their median MMSE score was 24 (limits: 18-26) (table 1), thus 
being classified as suffering from mild AD. The patients were generally independent 
when dealing with the basic activities of daily life even though some more complex 
activities were impaired. All patients were examined with a brain MRI which 
excluded the presence of cerebral vascular lesions or any cause of reversible 
dementia. 
The control group that we recruited for our study consisted of thirteen (13) 
age-matched normal subjects, six (6) men and seven (7) women, (median age: 72 
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years with limit ages 55-82 y). They were all right–handed. They had no history of 
neurological disease and their neurological examination was completely normal. 
 
B. Methodology 
 We performed our experiment in two phases. In the first phase, all AD 
patients were tested before any treatment was started. Immediately after the first 
phase, all patients received treatment with the cholinesterase inhibitor donepezil 
administered orally at 10 mg/day after the required titration. In the second phase of 
the experiment the whole procedure was repeated after 2 months of treatment in 
all patients except one (patient 11) who was lost to follow-up.  
The protocol was approved by the local ethic’s committee and, after being 
provided with detailed information about the aspects and the goal of the study all 
patients and normal subjects were willing and able to participate in the 
electrophysiological procedure. 
Prior to the electrophysiological examination, the patients and normal 
subjects were seated comfortably on a chair in a quiet examination room. A Nicolet 
Viking IV IES 405-1 EMG machine was used to record the compound muscle action 
potential (Cmap) of the right abductor digiti minimi in order to measure various 
parameters of motor evoked potential induced by TMS. TMS was applied by a 
Magstim 200 stimulator (Magstim Ltd., Withland Dyfed, UK) in accordance with the 
consensus guidelines [60].  
For our TMS experiment we used a circular coil with a diameter of 9 cm 
which was centered at the vertex of the scalp. The circular coil was chosen as 
opposed to a more focal eight-shaped so as to reduce the duration of the whole 
procedure and the related possible discomfort felt by the individuals tested. The 
centre of the coil was measured on the line between the nasion and the inion point 
in each patient to ensure the reproducibility of the procedure from the first session 
to the second one performed 2 months later.  The current in the coil was circulating 
counterclockwise. 
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The subjects were asked to perform a slight isometric voluntary contraction 
of the right abductor digiti minimi at around 20% of the maximum voluntary muscle 
contraction during the application of the TMS.  Both auditory and visual feedbacks of 
EMG activity were used to ensure the accuracy of the procedure. 
We measured two TMS parameters, the active motor threshold (aMT) and 
the silent period (SP). 
Active motor threshold (aMT) 
Active motor threshold is defined as the minimal intensity of cortical 
stimulation, which produces MEPs greater than 100μV and approximately to 200 μV 
in 50% of the consecutive trials during isometric contraction of the tested muscle 
when the muscle is at about 20% of the maximum voluntary contraction. The aMT 
was determined by gradually lowering the stimulator output from 60% of the 
maximal output. 
 As mentioned before, motor threshold is a neurophysiological TMS 
parameter which reflects the excitability of motor cortex. Its measurement in 
patients with Alzheimer’s disease can give very important information about the way 
this neurodegenerative disease affects the function of the cortical motor areas and 
consequently alters the motor behaviour of the patients. 
We chose to perform our experiment measuring the active motor threshold 
instead of the resting motor threshold (rMT) in order to avoid any technical errors 
arising from possible difficulties that patients with Alzheimer’s disease could exhibit 
in maintaining absolute rest in their muscles during the experimental procedure. 
Silent period (SP) 
Once the active motor threshold was determined we proceeded with the 
calculation of the silent period (SP) applying single-pulse TMS in the same groups of 
AD patients and normal subjects.  
Silent period is defined as the duration of interruption of electromyographic 
activity which follows the motor evoked potential (MEP) elicited in a muscle 
sustaining isometric voluntary contraction after the application of TMS in the 
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contralateral primary motor area (M1). Despite the inter-individual and 
intraindividual variation, the usual duration of the silent period in healthy individuals 
is around 200-220 msec. 
 It is assumed that the early part of the silent period is mediated by spinal 
mechanisms while the latter part is mediated by mechanisms interacting at the 
cortical level. The duration of the first part of the SP called the ‘spinal’ SP is almost 
always stable at around 50 -70 msec. It is ascribed primarily to multiple segmental 
mechanisms, including Renshaw cell recurrent inhibition, and activation of inhibitory 
Ia interneurons of the spinal level. The second part is determined by the interaction 
between interneurones at the cortical level which activate cortical inhibitory 
mechanisms. It is more variable in duration and is considered as the ‘cortical’ silent 
period [62].  
Silent period is considered as a direct indicator of cortical inhibition. It also 
provides useful evidence about the pathophysiological mechanisms that regulate 
cortical inhibition when measured in subjects under pharmacological agents which 
affect basic neurotransmitters such as acetylcholine or glutamatergic acid [53, 59].    
However, SP has not been extensively studied in AD patients until now. The 
main reasons for this were the considerable inter-individual variation of SP duration, 
the high degree of intraindividual asymmetry and the variable results when different 
examiners apply the TMS in the same subject [61]. It should also be noted that some 
patients with Alzheimer’s disease have difficulty collaborating efficiently. In our 
study we have tried to lessen the impact of these restricting parameters by 
recruiting AD patients in the early stage of the disease. Furthermore, in order to 
secure good collaboration and to avoid even subtle differences in the application of 
TMS, the same examiner was always used to carry out the procedure in both groups 
of patients and normal subjects.   
In our experiment we adapted the most widely used technique to determine 
SP. Immediately after the measurement of the aMT we raised the intensity of the 
output of the magnetic stimulator to 150 % of the motor threshold. Some seconds 
before the electromagnetic current was applied by the stimulator, the patients were 
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asked to perform a voluntary contraction of the targeted muscle (abductor digiti 
minimi) of about 50 % of the maximal voluntary contraction assessed by amplitude 
of the EMG response. The base time of the recordings was 500 milliseconds. 
The duration of the silent period is one of the main parameters used to 
assess cortical inhibition. SP duration is independent from the level of baseline EMG 
contraction, it increases with the strength of stimulation and is defined as the 
difference between SP onset and SP offset. However, the methods used to 
determine the onset and offset of SP vary widely in different studies. SP onset has 
been defined by: a) the onset of TMS, b) the MEP onset, c) the MEP offset, or d) 
when electromyography (EMG) drops below the volitional pre-TMS EMG level. 
Similarly, the SP offset has been defined by: a) the first return of any volitional EMG, 
b) the absolute return of EMG to the pre-TMS level, or c) when EMG no longer 
significantly differs from pre-TMS EMG level [63, 64]. 
The evaluation of the whole SP duration is also difficult to determine as 
sometimes it can be temporarily interrupted by an electromyographic breakthrough 
of short duration and low amplitude. This EMG breakthrough is called late excitatory 
potential (LEP) [65] and its appearance could lead to a miscalculation of the true 
duration of silent period. Sometimes, several LEPs can scatter the SP in a lot of 
valleys before the final return of full electromyographic activity. 
In our study we chose to measure the SP ‘valley’ defining the onset of SP by 
MEP offset and the offset of SP by the return of the electromyographic activity in 
amplitude which no longer differed from pre–TMS level, and not by the first return 
of any volitional EMG. In this way we avoided errors in our calculation of SP caused 
by possibly measuring false shorter valley duration due to the appearance of late 
excitatory potentials which would be incorrectly taken as the return of EMG activity. 
The duration of the silent period was analyzed as well as the presence or absence of 
LEPs. In the cases where LEPs appeared, their latency, amplitude and duration were 
also calculated. 
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C. Results 
All the results of the active motor threshold and silent period in the group of 
normal subjects and the group of AD patients were compared and statistically 
analyzed using the unpaired Student T test. In addition, we investigated a possible 
correlation between the MMSE score and the motor threshold in untreated AD 
patients using the Pearson correlation test. 
Results of the Active motor threshold (aMT) 
The results of each AD patient’s MMSE scores and active motor threshold 
before and after donepezil are summarized in Table 1.  
 
Table 1: Description of age, MMSE score and Active Motor Threshold (aMT) in the 
studied patients with mild AD. 
 
Patient Age, years 
MMSE score before 
donepezil 
MMSE score after 
donepezil 
aMT before 
donepezil 
aMT after 
donepezil 
1 73 26 26 34 34 
2 83 21 25 33 30 
3 58 26 28 33 35 
4 66 24 23 42 27 
5 75 18 18 40 40 
6 81 23 22 37 33 
7 70 23 24 39 36 
8 74 25 27 38 35 
9 75 21 22 33 30 
10 81 24 25 37 37 
11 81 25 NA 47 NA 
12 54 26 26 37 32 
13 72 21 22 34 30 
 
In the group of normal subjects the mean active motor threshold (aMT) was 32.8 % 
(SD +/- 7.7). 
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For the AD patients before treatment with donepezil the mean aMT was 37.6 % (SD 
+/- 3, 9) . 
The observed difference in the aMT between normal subjects and AD patients 
before treatment was statistically significant (p < 0.05). 
For the 12 AD patients who underwent the experiment after being treated for 2 
months with donepezil the mean aMT was 33.5 % (SD +/- 3.5).  
The difference in the aMT between normal subjects and treated AD patients was not 
statistically significant. The observed difference in the aMT in AD patients before and 
after treatment with donepezil was statistically significant (p < 0.05), regardless of 
the inclusion or exclusion of patient 11 (Figure.4). 
Figure 4. Distribution of individual values of aMT (expressed in %) in AD patients 
before treatment with donepezil (AD T0), in AD patients after 2 months of donepezil 
treatment (AD T+2) and in normal subjects (NLS). 
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Similarly, the mean MMSE score of the treated AD patients was slightly increased 
(24.00 ± 2.76) compared with the MMSE score of these patients before treatment 
(23.6 ± 2.40).  However, this difference was not so great as to reach statistical 
significance. 
When a Pearson correlation test was performed between the MMSE value and the 
value of the aMT in untreated patients, the obtained R showed a weak value of 0.04.  
Nevertheless, this was a positive value indicating a trend of the aMT to increase with 
the MMSE score (Figure.5).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Relationship between values of MMSE in untreated AD patients and the 
aMT. A weak positive correlation (R = 0.04) was found. 
 
Results of the Silent period (SP) 
The results concerning the Silent period (SP) for each group of subjects are 
presented below, starting with the results for the control group, continuing with the 
results for the AD patients before treatment and ending with the results for the AD 
patients after treatment.  
Control group - normal subjects: 
For the control group (Table 2.) the EMG following TMS generally showed the 
pattern of a MEP at a latency of around 20 ms followed by a silent period of variable 
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duration. LEP was observed in 1/13 subjects (7%).  For the one subject (L. 70 y.o.) 
who presented LEP the duration of silent period was 229 ms. 
The mean latency of the LEP was 67 ms, the amplitude was 487 µV and the duration 
was 111 ms These results, concerning the latency of the LEPs, were within the range 
described by the related literature [65, 66]. For the normal subjects the mean (+/- 
SD) duration of SP was 107.5 +/- 42.2 ms. When subject L. was included, the duration 
of SP was 116.8 +/- 52.6 ms.  
Table 2. SP duration and LEPs for normal subjects (control group). 
Normals LEP SP duration 
(ms) 
LEP duration 
(ms) 
LEP amplitude 
(µV) 
LEP latency 
(ms) 
SP duration if LEP 
present (ms) 
SP duration if 
LEP absent (ms) 
1 NO 125     125 
2 NO 132     132 
3 NO 58     58 
4 NO 122     122 
5 NO 187     187 
6 NO 89     89 
7 YES 229 111 487 67 229  
8 NO 47     47 
9 NO 71     71 
10 NO 145     145 
11 NO 136     136 
12 NO 116     116 
13 NO 62     62 
Mean  116.8 111 487 67 229 107.5 
SD  52.6     42.2 
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Patients group - AD  patients before treatment 
For the AD patients before treatment with donepezil (Table 3.), the mean duration of 
SP was 186.4 +/- 88.2 ms.  
Table 3.  SP duration and LEPs for AD patients before treatment with donepezil. 
AD before 
treatment 
LEP SP duration 
(ms) 
LEP duration 
(ms) 
LEP amplitude 
(µV) 
LEP latency 
(ms) 
SP duration if 
LEP present 
(ms) 
SP duration if LEP 
absent (ms) 
1 YES 262 18 1100 46 262  
2 NO 45     45 
3 YES 182 27 798 112 182  
4 NO 86     86 
5 YES 162 32 812 98 162  
6 YES 176 42 625 61 176  
7 YES 364 55 563 181 364  
8 YES 173 86 650 62 173  
9 NO 95     95 
10 YES 238 74 1800 94 238  
11 YES 223 68 625 102 223  
12 YES 285 49 368 134 285  
13 NO 132     132 
Mean  186.4 50.1 815.7 98.9 229.4 89.5 
SD  88.2 22,8 420.5 41.5 66.3 35.7 
 
The obvious increase observed in SP duration by comparison to normal subjects was 
proved significant statistically (p < 0.001). 
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In 9 out of 13 Alzheimer’s disease patients (69%)  LEPs were evident. The mean 
latency of the LEP was 98.9 +/- 41.5 ms, the mean amplitude was 815.7 +/- 420.5 µV 
and the mean duration was 50.1 +/-22.8 ms.  
In the 9 patients who presented LEP the SP valley appeared fragmented in multiple 
segments before the true return of full electromyographic activity.  In these patients 
the mean duration of the SP was 229.4 +/- 66.3 ms. A statistically significant 
difference was established by comparison to the duration of SP in normal subjects 
(p<0.001).  
For the 4 patients who did not exhibit any LEP, the mean duration of the SP was 89.5 
+/- 35.7 ms, a result which did not reach significant difference statistically compared 
to normal subjects.  
Patients group - AD  patients after treatment 
For the patients after treatment with donepezil (Table 4.) the mean duration of the 
silent period was 150.5 +/ 85.0 ms. There was no statistically significant difference 
with the duration of SP of normal subjects or with that of the AD patients before 
treatment. 
LEPs occurred in 5 out of 12 patients (42%) with a mean latency of 96.8 +/- 29.2 ms, 
mean amplitude of 860.4 +/- 225.9 µV and a mean duration of 46.6 +/- 21.9 ms. 
There was no statistically significant difference in latency, amplitude or duration of 
the LEPs between the patients before and after treatment with donepezil.  
In the 5 patients who presented LEP, the mean duration of the SP was 221.2 +/- 87.1 
ms which was not significantly different from the duration of SP in AD patients with 
LEP before treatment. 
In the 7 patients without LEP, the mean duration of the SP was 90,6 +/- 28.6 ms 
which was also not significantly different compared to the 4 patients without LEP 
before treatment and to the normal subjects. 
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Table 4.  SP duration and LEPs for AD patients after treatment with donepezil. 
AD after 
treatment 
LEP SP duration 
(ms) 
LEP duration 
(ms) 
LEP amplitude 
(µV) 
LEP latency 
(ms) 
SP duration if 
LEP present 
(ms) 
SP duration if LEP 
absent (ms) 
1 YES 274 52 662 137 274  
2 NO 112     112 
3 YES 139 23 854 73 139  
4 NO 140     140 
5 YES 261 36 614 102 261  
6 NO 54     54 
7 YES 214 41 1120 64 214  
8 NO 68     68 
9 YES 284 81 1052 108 284  
10 NO 94     94 
12 NO 86     86 
13 NO 80     80 
Mean  150.5 46.6 860.4 96.8 221.2 90.6 
SD  85.0 21,9 225.9 29.2 87.1 28,6 
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In the figures below there is an illustration of examples of SP in a normal individual 
(Figure 6.a.) and in two untreated AD patients where LEPs are present (Figure 6.b.). 
 
 
 
 
 
Fig.6a. SP in a normal individual (base time: 50 ms/division; amplitude: 200 
μV/division). 
 
   
 
Fig.6b. SP with presence of LEPs in two untreated AD patients (base time: 50 
ms/division; amplitude: 200  μV/division).  
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After performing our TMS experiment in the early AD patients under 
pharmacological manipulation with donepezil, the results showed a statistically 
significant difference for active motor threshold between AD patients and normal 
subjects and also between untreated AD patients and those treated with donepezil. 
Notably, an increase in the active motor threshold for the early AD patients who had 
never received any treatment was observed in comparison with normal subjects of 
the same age.   
After 2 months of treatment with 10 mgr of donepezil the motor threshold 
decreased significantly in the group of Alzheimer’s disease patients resembling the 
active motor threshold of the normal patients. Also a difference was noted in the 
duration of the silent period between AD patients before treatment with donepezil 
and normal individuals of the same age. In early AD patients the SP valley was found 
to be significantly longer in duration and also scattered with multiple LEPs when 
compared to the control group. After treatment with donepezil both the duration 
and shape of the SP resembled that of the control group more.   
Taking into consideration that the motor threshold reflects the excitability of 
the motor cortex, the increased aMT indicates a decreased cortical excitability in the 
early stage of Alzheimer’s disease.  The restoration of aMT after treatment with 
donepezil to levels close to those of the control group raised the issue of an 
important effect of the cholinergic mechanism of action of donepezil upon cortical 
excitability.  
 
3.3.2. SUBEXPERIMENT 1.  
The statistically significant decrease in the active motor threshold of early AD 
patients after receiving the achetylcholinesterase inhibitor donepezil enabled us to 
assume the existence of a cholinergic mechanism in the regulation of cortical 
excitability in early AD. Thus, we performed a supplementary experiment with a 
smaller group of patients in the early stage of Alzheimer’s disease who, instead of 
being treated with donepezil, would be treated with memantine for 2 months.  In 
this way we could observe the subsequent results of cortical excitability after the 
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prescription of a medication with a different mechanism of action from that of an 
achetylcholinesterase inhibitor. Unlike donepezil, which exerts its action by directly 
affecting the cholinergic system of the brain, memantine exerts its action in 
demented patients by mainly affecting the neurotransmitter glutamate.  
It is hypothesized that in the etiology of Alzheimer’s disease a dysfunction of 
glutamatergic neurotransmission is involved, manifested as a neuronal excitotoxicity 
due to the excess of glutamate in the brain. Consequently, the targeting of the 
glutamatergic system and specifically the NMDA receptors represents a new 
therapeutic option for AD.  Memantine is an NMDA receptor antagonist which binds 
to NMDA receptors on brain cells and blocks the activity of glutamate, therefore 
protecting neurons from excitotoxicity. In addition to its main mode of action, 
memantine also exerts an effect on the cholinergic system of the brain being an 
antagonist at alpha-7 nAChR. This could explain the initial worsening of cognitive 
function during early memantine treatment. However, alpha-7 nAChR up-regulates 
quickly in response to antagonism, which could explain the cognitive-enhancing 
effects of chronic memantine treatment. 
Taking into consideration the mode of action of memantine, the performance 
of our TMS experiment after treating early AD patients with this medication would 
lead to conclusions about the effect that certain neurotransmitters have on the 
function of the motor cortex. Also the comparison of the results of this sub-
experiment with those obtained by the experiment conducted under donepezil 
treatment might enable us to form a better understanding of the neuronal circuits 
involved in the regulation of the primary motor cortex.  
 
A. Patients and Methodology  
For our experiment with memantine we recruited five (5) more AD patients, 
four (4) women and one (1) man. The median age was 74 years (limit ages: 68-
75).The patients were in the early stage of the disease with a median MMSE score of 
24 (limits: 21-26). 
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We applied single-pulse TMS using the same methodology as in our experiment with 
donepezil performing the procedure in two phases, before and after treatment with 
memantine. We also calculated the same TMS neurophysiological parameters of 
active motor threshold and the silent period. 
As control group for this sub-experiment we used the same group of normal patients 
that was used in our experiment with donepezil. 
The subsequent results of this experiment between the group of normal subjects 
and the group of AD patients were also compared and statistically analysed by using 
the unpaired Student T test.  
 
B. Results 
Results of the Active motor threshold  
The mean active motor threshold (aMT) of the 5 AD patients before the initiation of 
treatment with memantine was 38,6 (SD  +/- 5,94). 
After treatment with memantine for two months the mean aMT was 39, 2 (SD +/- 3, 
96).   
The observed difference in the aMT between normal subjects and AD patients 
before treatment with memantine was statistically significant (p < 0.05). 
No statistically significant difference was observed in the results regarding active 
motor threshold for the AD patients before and after treatment with memantine. 
Results of the Silent Period 
AD patients before treatment 
The duration of the silent period for the 5 AD patients before treatment with 
memantine was 245, 8 +/- 83,7 ms. (Table 5). 
In comparison with the duration of SP in the group of normal subjects, this observed 
increase reached statistical significance (p<0, 05). However, we have to take into 
consideration the limitations of the small number of participants in the AD group in 
our interpretation of the results. 
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 3 out of the 5 patients presented LEP ,with a mean duration of 51 +/- 5, 57 ms, a 
mean amplitude of 1250,67 +/- 279,39 µV and a mean latency of 117, 33 +/- 48,69 
ms. In these 3 patients the SP appeared fragmented and its duration was  289 ,66 +/- 
75,95 ms.  
 For the 2 patients who did not display LEP, the duration of SP was 180 +/- 45,25 ms. 
 
Table 5: results of aMT, SP duration and presence of LEPs in AD patients before treatment 
with memantine. 
Patients Age MMSE Threshold SP 
Duration 
LEP SP Duration,  
LEP present 
SP Duration 
LEP absent 
LEP 
Duration 
LEP 
Amplitude 
LEP 
Latency 
1 75 24 31 253 1 253  56 1542 132 
2 68 25 44 212 0  212    
3 75 23 38 377 1 377  45 985 157 
4 71 26 45 148 0  148    
5 74 21 35 239 1 239  52 1225 63 
Mean 72.6 23.8 38.6 245.8  289.7 180 51 1250.7 117.3 
SD 3.05 1.9 5.9 83.7  75.9 45.2 5.6 279.4 48.7 
 
AD patients after treatment 
The duration of the silent period for the 5 AD patients after treatment with 
memantine was 238, 2 +/- 43, 7 ms. (Table 6.). 
There was no significant difference in the duration of SP between untreated patients 
and those treated with memantine. 
4 out of 5  AD patients  presented LEP after treatment with memantine with  a mean 
duration of 51,25 +/- 8, 47 ms, a mean amplitude of 1151,25 +/- 278,26 µV and a 
mean latency of 113, 33 +/- 24,067 ms. No significant difference is observed 
concerning the mean duration, latency and amplitude of LEP between untreated AD 
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patients and those treated with memantine. The duration of SP for the 4 patients 
who presented LEP was 244, 25 +/- 48 ms. For the one patient who did not display 
LEP the duration of SP was 214 ms.  
 
Table 6: results of aMT , SP duration and presence of LEPs  in AD patients after 
treatment with memantine.  
Patients Age MMSE Threshold SP 
Duration 
LEP SP Duration 
LEP present 
SP Duration 
LEP absent 
LEP 
Duration 
LEP 
Amplitude 
LEP 
Latency 
1 75 23 33 236 1 236  62 1024 120 
2 68 25 42 214 0  214    
3 75 25 40 301 1 301  53 850 142 
4 71 24 43 255 1 255  42 1236 105 
5 74 23 38 185 1 185  48 1495 85 
Mean 72.
6 
24 39.2 238.2  244.25  51.2 1151.2 113 
SD 3.0
5 
1 3.96 43.7  48  8.4 278.3 24.7 
 
 
The results of the Subexperiment 1 show that memantine intake does not have any 
effect upon active motor threshold or the silent period of early AD patients. These 
results combined with the results by our experiment with donepezil, show that in 
early AD patients the excitability of the primary motor cortex is regulated through 
cholinergic neuronal pathways. 
 
3.3.3. SUBEXPERIMENT 2.  
As the motor threshold reflects cortical excitability, our experimental 
finding of decreased motor cortical excitability in early AD was in accordance with 
what we had clinically observed in these patients in terms of diminished movement. 
In order to accumulate further evidence in our TMS study about the alertness of the 
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motor cortex to produce a movement in early Alzheimer’s disease we decided to 
perform another experiment not linked to TMS. This would provide more direct 
answers about the ability of the motor cortex of early AD patients to provide a 
motor reaction.  We also performed this experiment under the pharmacological 
manipulation of donepezil, keeping in line with our standard procedure so far. In this 
way we could further examine our early observations that the ‘hypomovement’ 
which is clinically present in early AD is linked to a decreased excitability of the 
primary motor cortex and is probably influenced by the cholinergic system. 
Thus, we developed an experiment where we studied the reaction time after 
giving a simple visual stimulus to a group of early AD patients and we compared 
them to a group of normal individuals. We specifically measured the single motor 
reaction time (sRT) and the single muscular movement time (sMT). 
 
A. Patients 
We recruited eight (8) more AD patients, two (2) men and (6) women. Their mean 
age was 69 years (limit ages: 62-81). They were all in the initial stage of their disease 
with a median   MMSE of 26 (limits 24-29).  
The control group consisted of fifteen (15) normal individuals, six (6) men and eight  
(8)  women with a median age of 71 years (limit ages 63-77). 
 
B. Methodology 
We applied the same inclusion criteria in the patients group which had been 
applied to the patients of the previous TMS experiments so, we ensured that the 
patients did not suffer from any other neurological disease, their neurological 
examination was completely normal, they had a normal brain MRI and they were not 
under treatment with any medication that could possibly have an effect on the 
central nervous system or affect the cortical excitability in any way. 
All patients and all normal subjects agreed to participate in the experiment 
and their consent was approved by the local ethics committee. We performed the 
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experiment before any treatment was started and also after 2 months of treatment 
with 10 mgr of donepezil and we compared the results. 
We assessed Simple reaction time (sRT) by using a random visual stimulus. 
Patients and normal subjects were comfortably seated in a chair and they placed 
their right index finger on a button. A surface electrode was stuck on the skin above 
the body of the extensor indicis proprius muscle in order to record the 
electromyographic activity produced by the movement of this muscle which moves 
the index finger. In this way the simple muscular movement time (sMT) could be 
determined. This experiment was performed with the same Nicolet Viking IV IES 405-
1 EMG machine previously used for our TMS experiments. 
The patients and normal subjects were instructed to push the button as 
quickly as possible after a randomly computer generated visual red flash. The latency 
for the movement response (sRT) and the latency for the electromyographic 
response (sMT) were both recorded by a CED1401 system. 
 
C. Results 
The mean simple reaction time (sRT) was 207, 3 +/- 25, 5 msec in normal subjects. 
(Table 7.) 
The mean sRT was 253, 0 +/- 32, 5 ms in AD patients before treatment with 
donepezil was initiated (Table 8.) 
The difference in sRT between these two groups reached statistical significance (p < 
0,001). 
The mean sRT was 229, 9 +/- 30, 6 ms in AD patients after treatment with donepezil. 
A statistically significant difference between the treated and untreated patients ( p < 
0,002 ) was established. 
The difference in sRT between not treated with donepezil patients and normal 
subjects was even more significant statistically (p < 0,001).   
The mean single muscular movement time (sMT) in normal subjects was 159,3 +/- 
29,3 msec.  
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The mean sMT for the untreated patients was 203, 8 +/- 29, 0 msec. The difference 
by comparison to normal subjects was very significant statistically (p < 0,001). 
The mean sMT was 180, 8 +/- 32, 2 msec in AD patients after 2 months treatment 
with donepezil. a statistically significant difference in sMT between the treated and 
untreated AD patients (p<0,001) and between treated AD patients and normal 
subjects (p< 0,001) was established.  
Tables 7 and 8 summarize the results of   subexperiment 2. 
 
Table 7:  Simple reaction time and simple movement 
time in the group of normal subjects 
 
 Sex Age sRT sMT   
1 F 76 245 198 
2 M 71 220 175 
3 M 68 204 154 
4 F 77 251 199 
5 F 70 200 154 
6 M 77 205 161 
7 M 68 168 147 
8 F 66 174 130 
9 M 72 189 140 
10 F 76 202 142 
11 M 73 248 201 
12 F 72 221 172 
13 F 71 200 141 
14 F 67 184 132 
15 F 63 199 144 
Mean  71.33 207.33 159.33 
SD  4.24 25.48 24.31 
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Table 8: Simple reaction time and simple movement time in the group of AD patients, 
before and after treatment with donepezil.  
 
 Sex Age MMSE 
before 
donepezil 
MMSE 
After 
donepezil 
sRT  
before 
donepezil 
(SD) 
sRT             
after     
donepezil 
(SD) 
sMT 
before 
donepezil 
(SD) 
sMT            
after 
donepezil 
(SD) 
1 F 66 24 24 278.28 
(32.420 
217.97 
(11.97) 
233.74 
(25.55) 
169.72 
(22.33) 
2 M 75 25 24 255.46 
(31.35) 
226.78 
(36.45) 
215.68 
(28.45) 
191.23 
(30.58) 
3 F 81 29 28 240.45 
(49.38) 
239.18 
(66.03) 
197.93 
(36.22) 
183.08 
(56.56) 
4 M 68 26 27 239.67 
(19.56)  
224.76 
(22.62) 
192.45 
(25.39) 
172.76 
(23.74) 
5 F 70 26 27 244.04 
(29.8) 
236.75 
(17.8) 
211.15 
(31.2) 
198.6 
(26.99) 
6 F 62 27 26 221.69 
(23.79) 
224.76 
(22.62) 
168.31 
(23.95) 
170.69 
(22.37) 
7 F 74 25 26 285.15 
(39.52) 
256.73 
(39.01) 
196.14 
(35.56) 
174                
(37.4) 
8 F 64 29 27 259.69 
(34.46) 
212.37 
(28.29) 
215.03 
(25.66) 
286.31 
(37.47) 
Mean  70 26.37 26.12 253.05 
(32.53) 
229.91 
(30.59) 
203.8 
(28.99)   
180.79 
(32.18) 
 
 
The results of Subexperiment 2, which show significantly increased sRT and sMT 
in early AD patients compared to normal subjects of the same age, confirm the 
clinical observation of decreased mobility in early AD patients. The improvement of 
sRT and sMT after donepezil intake supports a cholinergic modulation of the 
alertness of the primary motor cortex in the early stage of Alzheimer’s disease. 
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CHAPTER  4. 
DISCUSSION 
4.1. THE ALTERED EXCITABILITY OF THE MOTOR CORTEX IN EARLY AD 
The results of our TMS experiments show a difference in the active motor 
threshold of patients in the initial stage of Alzheimer’s disease in comparison to age-
matched normal subjects. Given that the motor threshold is a direct reflection of 
cortical excitability our experimental study indicates a modulation in the excitability 
of the primary motor cortex in early AD. Our results are in accordance with a fair 
number of TMS studies performed prior to ours. Regardless of the differences in the 
various studies in terms of the methodology, the stage of the disease of the 
participating patients and whether the modulation of cortical excitability increases 
or decreases, the common factor is a change in the excitability of the motor cortex in 
Alzheimer’s disease. The TMS experimental paradigms, starting from the first study 
conducted by Perretti et al. [48], continuing with the studies of De Carvalho et al. 
[49], Pepin et al. [50], Pennisi et al.  [51], Ferreri et al.  [52] and more recently those 
of Nardone et al. [53] and Khedr et al.  [58], have all shown an alteration in motor 
threshold in patients suffering from Alzheimer’s disease.  
In our TMS study we found a statistically significant increase in the active 
motor threshold in the group of AD patients compared to the control group which is 
suggestive of a decreased excitability of the motor cortex in early AD.  Most of the 
older studies [49, 50, 51, 52] with the exception of the study of Perreti [48] have 
shown a decrease in motor threshold leading the investigators to assume an 
increased excitability of the motor cortex in Alzheimer’s disease.  This discrepancy 
between our study and the others can be explained if we look more carefully into 
some details in the organization of each study. In our experimental paradigm we 
recruited patients in a very early stage of Alzheimer’s disease (mean MMSE score of 
24).The majority of the previous studies which identified decreased motor threshold 
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in Alzheimer’s disease had recruited more mixed groups of patients. Pepin et al. [50] 
and Pennisi et al [51] in their experiments applied single-pulse TMS in a  
heterogenous group of patients with moderate and advanced Alzheimer’s disease.  
Ferreri et al. [52]   included patients with both mild and moderate disease severity. 
However, the study conducted by Nardonne et al. in 2008 [53] has shown 
similar results to ours regarding active motor threshold. Even though the results of 
Nardonne et al. did not reach the statistical significance of our study, an increase 
both in resting and active motor threshold was evident in their group of AD patients 
when compared to normal subjects.  This increase was more profound for the active 
motor threshold (aMT), which is similar to our results. 
The study of Khedr et al. [58] supports our results concerning increased 
active motor threshold in early AD patients. These investigators organized their 
study by separating their patients into 3 different groups according to which stage of 
the disease they were classified: mild, moderate or advanced disease. It was 
revealed that the active motor threshold was increased in the early (mild) stage of 
AD compared to normal individuals even though the increase did not reach statistical 
significance. However, their findings clearly showed decreased motor cortical 
excitability in the initial stages of AD which is in agreement with our experimental 
results.  More interestingly it was shown by Khedr et al. that the initial increase of 
the active motor threshold noted in the mild stage of AD, was followed by a gradual 
decrease of this parameter from mild to moderate and finally to more advanced 
stages. After the early stages, the more the disease progressed the more the motor 
threshold diminished exhibiting an increase in the excitability of the motor cortex as 
the disease evolved.  
While the results of our study, which are supported by those of Nardonne 
and Khedr,  demonstrate a decrease in the excitability of the motor cortex in the 
early stages of Alzheimer’s disease, other studies performed with more advanced 
patients [ 50, 51,52] revealed different results. These, especially the study of Perreti 
which included severely affected patients, displayed results which showed a 
significant increase in the excitability of the motor cortex in advanced disease. Thus, 
it can be concluded that an awareness of the exact stage of the disease of the 
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patients who participate in any TMS experiment which evaluates motor threshold, 
and consequently cortical excitability, is crucial. The stage of the disease seems to be 
determining factor for the modulation of the excitability of the primary motor cortex 
in Alzheimer’s disease.  The careful review of the methodology and results of all the 
previous studies in comparison with ours indicates that AD in the initial stages 
induces a decrease in the excitability of the primary motor cortex followed by a 
gradual increase as neurodegeneration evolves. This outcome allows us to conclude 
that, as regards cortical excitability, Alzheimer’s disease is an evolving process. The 
pattern that it follows resembles the one described for amyotrophic lateral sclerosis 
(ALS), a neurodegenerative disease which has also been examined for the effect it 
exerts upon the excitability of the motor cortex. It was found that in ALS the 
threshold of motor cortex varies throughout the evolution of the disease displaying a 
pattern of decreased threshold in the initial stages (increased  cortical excitability) 
followed by a significant increase as the disease evolves (decreased cortical 
excitability) [67]. Thus, even if Alzheimer’s disease is not primarily a motor system 
disease like amyotrophic lateral sclerosis, it seems to affect the excitability of motor 
cortex in a similar manner to ALS but in terms of qualitative instead of quantitative 
characteristics.  This is an interesting observation which could indicate that the 
phenomenon of variability in cortical excitability in relation to the state of the 
disease might possibly be a common factor in other neurodegenerative diseases of 
the central nervous system as well.  
The established conclusion that the alteration of the excitability of the motor 
cortex in AD is directly connected to the stage of the disease not only presents a new 
view of Alzheimer‘s disease as a dynamic evolving process regarding its effect upon 
the motor areas of the brain, but also expands our understanding of certain clinical 
aspects of the disease.  Our finding of decreased excitability of the primary motor 
cortex in the early stages of AD can be associated with the clinical observations of 
the motor behaviour that the patients exhibit at disease onset. 
As already stated, the patients in the initial stages of Alzheimer’s disease 
display a pattern of restricted motor behaviour. They exhibit less facial micro 
expressions when they express emotion or when they participate in a situation that 
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demands alertness. They are slower both in the initiation of their motor reaction and 
in the execution of a certain movement when compared to unaffected individuals of 
the same age. If we combine the results of our study of motor threshold with the 
model suggested by Brown and Pluck [41] which views goal-directed behaviour as 
the outcome of a close interaction between cognitive and motor function, we could 
link the decreased excitability of the motor cortex in early AD with the observed 
changes in the motor behaviour of these patients. The primary motor area (M1) is 
responsible for the final implementation of any goal–directed movement which has 
been formerly inspired and programmed under the dynamic co-operation between 
the limbic system and the striato-thalamo-cortical circuit. Therefore, any change in 
the excitability of M1 causes an alteration in the motor behavior of the individual. 
According to this line of thought, the increased active motor threshold in early AD 
reflects a hypo-excitable motor cortex. A hypo-excitable motor cortex is less reactive 
to any external stimulus rendering the patient less likely to respond with the proper 
latency, amplitude and velocity of any necessary movement. This finally leads to a 
pattern of hypo-movement in the affected individual. Hence, our neurophysiological 
finding of decreased excitability of the motor cortex in the early AD patients 
pathophysiologically explains the differences from normal motor behaviour in the 
form of diminished movement. 
The correlation we have hypothesized exists between the excitability of the 
motor cortex and the type of motor behaviour exhibited by AD patients is further 
enhanced by the TMS studies which were conducted in individuals in more advanced 
stages revealing an increase in the excitability of the motor cortex at these stages 
[50, 51, 52]. We have already said that the patients with advanced disease display 
increased mobility in a form of disinhibited movement when compared to normal 
individuals. They have increased muscle tone, they engage in stereotypical and 
searching behaviour and they pace and wander incessantly often resulting in falls. 
These patients displayed increased excitability of the motor cortex when tested with 
TMS. Using the same analogy that we formerly used for the early stages of the 
disease we can assume that the excessive movement of the more severely affected 
AD patients is a reflection of a hyperexcitable -disihibited motor cortex. A more 
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excitable motor cortex is more prone to react with excessive movement in any given 
situation, illustrating the hyperactive, ‘hyperkinetic’ AD patient that most of the 
clinicians are very familiar with.  
 
4.2. THE ROLE OF THE CHOLINERGIC SYSTEM IN THE DECREASED 
CORTICAL EXCITABILITY  
The probable correlation between the decreased excitability of the primary 
motor cortex and the motor behaviour of the early AD patients, gave rise to the 
question of how exactly Alzheimer’s disease induces the decrease in the excitability 
of the motor cortex in the early stages given that in these stages the primary motor 
cortex is spared from the neuropathological hallmarks of the disease [19]. Various 
previous studies [52, 54, 56, 57] have used pharmacological agents to examine the 
possible biochemical pathways which may affect cortical excitability in AD. The 
cholinergic hypothesis that connects the disturbed acetylcholine output with the 
impaired cognitive function of the affected individuals from disease onset is well 
known [68, 69]. Also well known is the beneficial effect of the acetycholinesterase 
inhibitors in the cognitive function of the AD patients [70, 71, 72]. Hypothesizing a 
possible additional role of the cholinergic system upon the motor control of AD 
patients as well, we conducted our TMS experiment in our patient group before and 
after the daily treatment with 10 mg of the acetylcholinesterase inhibitor donepezil. 
Our experimental results confirmed our hypothesis as they clearly showed that after 
two months of treatment with 10 mg of donepezil daily, the active motor threshold 
of the AD patients significantly decreased to values close to the aMT of the normal 
individuals. 
The alteration in the form of ‘normalization’ of the active motor threshold 
after the oral administration of donepezil demonstrates the existence of a functional 
pathophysiologic mechanism in the regulation of the excitability of the motor cortex 
in early AD. This mechanism seems to be   under the control of the cholinergic 
system. Thus, by attributing this critical role to the cholinergic system, a plausible 
explanation is given for the altered excitability of the primary motor cortex in early 
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AD. Besides, no subclinical cortical atrophy or any other neuropathology can be 
traced in the motor areas of the patients in the initial stages of the disease which 
could explain the changes in cortical excitability as it is the case in the more 
advanced stages. So, based on our experimental results, we assumed that the 
function of the cholinergic system is at the root of the decreased excitability of the 
motor cortex in early AD.    
In order to further test the validity of our hypothesis concerning the critical 
role of acetylcholine upon cortical excitability and motor function in AD, we 
conducted our first supplementary TMS sub-experiment on a small group of AD 
patients by administering a pharmacological agent (memantine) which does not 
implicate the cholinergic system. Memantine, as a NMDA receptor antagonist, 
mainly affects the neurotransmitter glutamate. Our results showed no difference for 
active motor threshold in the group of the AD patients before and after 2 months of 
treatment with memantine. This result validated our hypothesis regarding the 
significant role of the cholinergic system in the regulation of the excitability of the 
motor cortex in AD. It is also in accordance with the existing literature relating to the 
capacity of memantine to affect the motor threshold [71]. Additionally, our sub-
experiment with memantine provided more experimental data about the difference 
in the active motor threshold between early AD patients and normal subjects. The 5 
early AD patients who participated in the experiment with memantine displayed 
increased active motor threshold when compared to the normal subjects, like the 13 
AD patients of our main experiment with donepezil. This augmented the sample of 
our patient group giving further statistical validation to our results.  
The next question which should be answered was about the exact manner in 
which the cholinergic system exerts such an impact on the excitability of the motor 
cortex of the affected individuals. According to the cholinergic hypothesis, the 
cognitive dysfunction of the AD patients is attributed to the degeneration of the 
cholinergic neurons in the basal forebrain (nucleus basalis of Meynert, medial septal 
nucleus and diagonal band of Broca) and the loss of cholinergic transmission in the 
neocortex. This hypothesis is supported by studies pointing out that pharmacological 
agents which act by potentiating the central cholinergic function (donepezil, 
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rivastigmine and galantamine) have a positive symptomatic effect in the treatment 
of AD patients, especially in the early stages[72, 73].  
It is known from the literature [74] that the degeneration of the cholinergic 
pathways which is traditionally believed to occur in Alzheimer’s disease is also 
observed in normal ageing but to a far lesser extent. The cholinergic neurons of basal 
forebrain have been assumed to undergo moderate degenerative changes during 
normal ageing resulting in hypofunction of the cholinergic system which is related to 
the deterioration of the memory.  However, a recent study conducted by Schliebs 
and Arendt in 2011 [75], presented results from experiments in humans and in rats 
which seriously challenge the commonly accepted view about cholinergic neuronal 
loss during normal ageing. This study suggests that whereas in pathological ageing, 
such as Alzheimer’s disease, an actual loss of cholinergic neurons of the basal 
forebrain is evident, normal ageing and mild cognitive impairment are not 
characterized by cholinergic neuronal loss but by a functional impairment of the 
cholinergic synapse.  These investigators stated that although in moderate and 
advanced stages of Alzheimer disease a severe impairment of the cholinergic 
innervation of the basal forebrain is extensively displayed, this is not the case in mild 
AD; in the very early stages of AD no true cholinergic neuronal loss is evident in the 
basal forebrain. Instead, a process similar but more intense to that of normal ageing 
and mild cognitive impairment seems to take place. According to these investigators, 
a modulation of the synaptic cleft associated with a dysfunction of the cholinergic 
neurons and a loss of signalling by the nerve growth factor is what happens in these 
neurons. This results in a dysfunction of the cholinergic neurons without true 
neuronal loss in mild AD. More interestingly, Arendt and Shliebs have stated that the 
cholinergic dysfunction is triggered by the presence of amyloid therefore connecting 
the biochemical dysfunction with the protein which holds the key role in the etiology 
of AD. Indeed, they provided abundant evidence that amyloid may trigger 
cholinergic dysfunction through action on a7-nAChR, by affecting NGF signalling, 
mediating tau phosphorylation, interacting with achetylcholinesterase, and 
specifically affecting the proteome in cholinergic neurons.   
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It is common knowledge that the basal forebrain BF), the area of the brain 
which is richer in cholinergic neurons, is connected to the primary motor cortex (M1) 
indirectly via basal ganglia and prefrontal cortex. Though, evidence recently 
obtained from animal experiments [76, 77] have shown that besides this indirect 
pathway, there are also direct connections from the basal forebrain and particularly 
from the nucleus basalis of Meynert to the motor cortex in rats.  Through those 
direct connections, a possible alteration in the cholinergic function of basal forebrain 
can directly affect the function of the primary motor cortex causing changes in 
cortical excitability. In the light of this new experimental evidence, the increased 
active motor threshold in our group of early AD patients could be seen as a 
reflection of a defective function of these connections between BF and M1 due to 
cholinergic deficit which according to Arendt and Schliebs is caused not by 
cholinergic neuronal loss but is due to a functional disturbance of the cholinergic 
neurons. The immediate restoration of the aMT, after treatment with donepezil, to 
values close to those of normal subjects is in keeping with our hypothesis. The 
existence of a direct pathway between the basal forebrain and the primary motor 
area provides a very persuasive explanation for the effect that a cholinergic 
dysfunction exerts upon the excitability of the motor cortex in early AD patients. A 
reduced cholinergic output results in decreased excitability of the motor area which 
is clinically translated into altered motor behaviour of the patients in the form of 
restricted movement.   
After correlating the results of our TMS experiment concerning increased 
motor threshold in early AD patients with the hypo-movement that these patients 
display and subsequently assuming the role of the cholinergic system as the 
underlying regulating factor, we judged it necessary to explore our conclusions 
further by implementing an experimental procedure other than TMS.  Thus, we 
performed our second sub-experiment by examining the simple reaction time in a 
group of patients in the early stages of Alzheimer’s disease before and after 
donepezil intake. The two parameters we assessed, the latency of the movement 
response (sRT) and the latency of the muscular response (sMT) were found to be 
significantly longer in the patient group than the control group. These findings are 
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supported by relevant literature which shows a prolongation of the reaction time in 
people affected by neurodegenerative cognitive disorders, Alzheimer’s disease 
included [78, 79]. One could argue that this differentiation in reaction time may 
reflect a distraction of attention or defective visual processing rather than a 
dysfunction of the motor system. Although this could happen in some 
neurodegenerative disorders such as Lewy Body Dementia due to the specific 
impairment of the anatomical structures involved in attention focusing and visual 
processing, it is not the case with Alzheimer’s disease. While some studies show 
some differences in visually evoked potentials between normal individuals and 
patients with Alzheimer’s disease [81] there is no clear and consistent evidence from 
the literature suggesting specific visual or attention deficit in AD in the early stages 
of the disease. 
The prolongation of both sRT and sMT reflects a delayed motor response in 
the AD patients after a simple visual stimulus by comparison to normal subjects.  
This delayed motor response is indicative of a lower capacity of the primary motor 
cortex of the affected individuals to react as fast as the normal subjects when 
responding to a certain visual stimulus. This finding is in agreement with the results 
of our TMS experiment showing increased active motor threshold in early AD 
patients. It is obvious that an increased motor threshold reflects a hypo-excitable 
motor cortex which is less able to react quickly after a certain stimulus, leading to a 
delayed motor reaction of the affected individual. In this way our reaction time 
experiment serves as further confirmation of the main argument of our TMS 
experiment about decreased excitability of the primary motor cortex in patients at 
the initial stages of Alzheimer’s disease. It also supports the correlation we propose 
between the impaired function of the motor cortex in early  AD and the impaired 
motor behaviour exhibited by the affected individuals in the form of hypo-
movement. 
We also observed that after treating the patients in early AD for 2 months 
with donepezil daily, both parameters (sMT) and (sRT) significantly decreased in 
duration, reaching a level that very much resembled that of the control group. The 
normalization of reaction time after donepezil intake outlines the important role of 
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the cholinergic system in the regulation of the mechanisms which control the ability 
of the primary cortex to provide a certain motor reaction in a certain time frame. 
This is in agreement with the results of our TMS experiment concerning 
normalization of the active motor threshold after donepezil intake. It is evident from 
the reaction time experiment that the restitution of acetylcholine renders the motor 
cortex of early AD patients more excitable compared to the state before treatment. 
A more excitable motor cortex can react faster to a stimulus, is more ready to 
initiate a certain movement in a reduced latency and finally, more able to perform 
the motor task in a shorter time frame. Thus, this experiment strongly supports our 
argument that the cholinergic system is the regulating factor in the function of 
primary motor cortex in early AD, being responsible for the differentiation in motor 
behaviour that these patients exhibit by comparison to normal individuals.  
 
4.3. EVALUATION OF THE MOTOR BEHAVIOR IN EARLY AD BEYOND 
EXCITABILITY:  ASSESSMENT OF CORTICAL INHIBITION 
In order to explore the exact manner in which the motor behaviour of the 
early AD patients is closely connected to the particular function of their motor cortex 
more thoroughly, we wanted to examine the neuronal circuit which is involved in a 
generated movement holistically This circuit starts from the pyramidal cells of the 
primary motor area (M1), passes through the alpha-motoneurons of the spinal cord 
and terminates in the contralateral contracted muscle. The motor threshold is a 
measure of the ability of the pyramidal cells to produce descendant volleys when 
they are stimulated by TMS. The descendant volleys produced activate the alpha-
motoneurons at the spinal level. This leads to the genesis of a motor evoked 
potential (MEP) in the targeted muscle as a final response to the stimulation of the 
contralateral motor area of the brain.  However, we did not want to form our 
conclusions about motor function in early AD based only upon the initial part of the 
neuronal circuit. This would have been the case if we had restricted the evaluation of 
the motor threshold as a reflection of the ability of the pyramidal cells to fire volleys 
to the spinal alpha-motoneurons. Instead, we decided to proceed further by 
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examining whether voluntary muscle contraction could be impaired in AD in other 
areas   of its functional route apart from altered cortical excitability and, if so, to 
identify the possible causes of such impairment.  Given that TMS activates different 
excitatory and inhibitory corticospinal pathways which influence the voluntary 
contraction, we also decided to calculate the silent period in addition to the active 
motor threshold. 
Silent period is a neurophysiological TMS parameter which is considered as 
an indicator of cortical inhibition. The duration of silent period defined as the 
difference between SP onset and SP offset is the parameter which is more widely 
assessed. It provides useful information about the specific ways by which the cortical 
inhibitory mechanisms affect voluntary muscle contraction. In addition to its role as 
an indicator of cortical inhibition, silent period is a more ‘active’ test for the 
assessment of voluntary muscle contraction. By definition, silent period is the 
duration of interruption of electromyographic activity which follows the production 
of a motor evoked potential (MEP) in a muscle sustaining isometric contraction after 
the application of TMS in the contralateral primary motor area (M1). Thus, by 
evaluating the silent period we were   able to observe the voluntary muscle 
contraction in a more dynamic and functional way at a postsynaptic level, surpassing 
the ‘static’ approach that offers the sole evaluation of the excitability of MI through 
the calculation of the motor threshold only.  Subsequently, a connection between 
the decreased excitability of the motor cortex in early AD and the state of function of 
the inhibitory mechanisms involved in the regulation of the movement could be 
established. 
Our TMS study has shown that the duration of silent period of the patients at 
the initial stages of Alzheimer’s disease was significantly increased in comparison 
with the SP of normal individuals of the same age.  A more thorough and detailed 
study of our results revealed that not only the duration but also the morphology of 
the silent period was significantly different in AD patients.  In particular, we have 
made the interesting observation that the ‘valley’ of the silent period which is 
defined as the interval between  MEP offset and return of full electromyographic 
activity, was more heterogeneous in the group of patients than it was in normal 
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individuals . The SP valley in AD patients, instead of having the shape of an isoelectric 
almost flat line due to complete cessation of any electromyographic activity, actually 
displayed a fragmentation in various segments due to the frequent appearance of 
late excitatory potentials (LEPS). 
A late excitatory potential (LEP), as already stated in a previous chapter, is an 
electromyographic breakthrough of short duration and low amplitude which, when it 
appears, scatters the valley of the silent period spoiling its linear form. LEPs are 
produced only when the tested muscle actively performs a voluntary contraction. 
LEPs are absent when the tested muscle is at rest [65]. As SP emerges after the 
stimulation of M1 at the 150% of the motor threshold (which in our study was the 
active motor threshold) this can justify the appearance of LEP in our control group 
even though it was rare (only one person in the control group presented LEP). The 
TMS studies which have assessed silent period in normal individuals [81, 82,] and 
those which have assessed SP in AD patients [55, 58, 59], have calculated the resting 
motor threshold instead of active motor threshold as we did. This can explain the 
scarcity of evidence from the literature regarding the appearance of LEP in AD 
patients and their appearance in our own study.  Regarding the etiology of LEPs, the 
related literature [64, 65, 66], provides some possible explanations for their 
appearance attributing them to the activation of slow motor pathways or to the 
activation of reflex pathways. The most prominent hypothesis though, addresses 
them to cortical disinhibition [65]. The malfunction of the inhibitory mechanisms of 
the brain which regulate the muscle contraction permits the release of late 
excitatory potentials during a period which should be characterized by total silence 
in electromyographic activity. 
In our experimental TMS study the appearance of LEPs was rare in the group 
of normal subjects as already stated. Only 1 out of the 13 subjects (7%) which had 
been tested displayed them. This result is not very distinct from that referred in the 
available literature (2-3%) [64]. On the contrary, in the group of early AD patients 
LEPs were very frequent as they appeared in 9 out of the 13 patients tested (69%). A 
very interesting observation was that the presence of LEPs was in line with the 
prolongation in the duration of silent period for both groups.  The absence of LEPs 
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was compatible with a silent period significantly shorter in duration.  This 
observation allowed us to conclude that the increased duration of the silent period 
in our early AD patients is closely related to the frequent appearance of late 
excitatory potentials which scatter the SP valley in various segments before the final 
return of full electromyographic activity.  Attributing the appearance of LEP to 
cortical disinhibition, as the data from the literature suggests, we can assume a 
disturbance in the function of the cortical inhibitory mechanisms of the brain in the 
early stages of Alzheimer disease which results in a more frequent appearance of 
late excitatory potentials. LEPs scatter the SP valley in multiple segments finally 
leading to a prolongation of silent period in comparison with normal individuals. 
However, there has not been extensive research about the evaluation of 
silent period in Alzheimer’s disease using TMS experiments so far. The relevant 
literature is rather scarce [48, 58, 83]. Most probably this can be attributed to 
technical restrictions arising during the procedure of the calculation of SP [73] and 
also to the difficulties that the AD patients have in terms of good collaboration which 
is necessary for the assessment of this parameter. The first TMS study in Alzheimer’s 
disease performed by Peretti et al [48] indicated a silent period with decreased 
duration in the patient group in comparison with the normal subjects. However, we 
have to keep in mind that this study included a large number of patients in advanced 
AD. Liepert et al [83] have concluded no difference in the duration of silent period 
between AD patients and normal subjects. The study of Khedr in 2010 [58] 
investigated the silent period in AD patients in each stage of their disease (mild, 
moderate, advanced). This study displayed a clear increase in the duration of the 
silent period in the patient group by comparison to normal individuals. More 
importantly, this increase was already prevalent in the mild  stage, thus supporting 
the validity of  our own study about increased duration of silent period in patients at 
the initial stages of Alzheimer’s disease.  Nevertheless, although the study of Khedr 
confirmed our results concerning the prolonged duration of SP in early AD, no 
information was given about the shape of the SP valley. Until now, with the 
exception of our experimental paradigm there has not been any evidence available 
from previous TMS studies suggesting that the appearance of LEP can cause a 
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fragmentation and finally a prolongation of the silent period. Maybe the frequent 
appearance of LEPs in early AD should be considered as a potential biomarker in the 
future but more studies with larger number of patients are required to investigate 
this further. 
 
4.4. THE CHOLINERGIC SYSTEM AND IMPAIRED CORTICAL INHIBITION 
IN EARLY AD 
The prolongation of the silent period in the group of early AD patients had to 
be attributed to a certain pathophysiologic mechanism. The second phase of our 
experiment, when we reexamined all our patients after treating them with the 
acetylcholinesterase inhibitor donepezil for two months, provided a very plausible 
explanation. In particular we observed that after treatment with donepezil the 
duration of the silent period of the AD patients was significantly decreased in 
comparison with its duration prior to treatment.  The duration of SP actually became 
much closer to that of the normal subjects to a point where there was no statistically 
significant difference between the SP of normal individuals and the SP of the AD 
patients treated with donepezil. The shortening of SP duration was due to the 
decrease in the occurrence of LEPS after donepezil intake. Our experiment has 
shown that in the group of untreated patients, 9 out of 13 displayed LEPs while in 
the group of patients treated with donepezil this occurrence dropped to 5 out of 13 
patients (a reduction from 69% to 42%).The restoration of the silent period both in 
morphology and duration after treatment with donepezil, was clearly indicative of a 
functional change in the inhibitory mechanisms of the brain given that silent period 
is a reflection of cortical inhibition. The fact that donepezil is an acetylcholinesterase 
inhibitor enabled us to assume a key role of the cholinergic system in the regulation 
of the inhibitory neuronal pathways of the brain. 
The only studies which have investigated the direct impact of cholinergic 
pharmacological agents upon the silent period of patients suffering from Alzheimer’s 
disease are ours and that of Liepert et al [83]. In the study of Liepert, the 
investigators calculated the silent period in the patient group before and after the 
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administration of donepezil for one week. No difference in the duration of SP was 
found between AD patients and normal subjects either before or after the 
administration of donepezil. Due to the scarcity of relevant literature, and given the 
contradictory results between our study and that of Liepert, our sub-experiment 
with memantine was very significant in order to test our conclusion concerning the 
important effect of the cholinergic system upon the duration and morphology of 
silent period in early AD.  This experiment helped to create a clearer picture of 
certain biochemical circuits which regulate the inhibitory mechanisms of the brain 
during voluntary muscle contraction given that memantine acts through glutamate. 
After treating the AD patients with 10 mgr of memantine daily for two months, no 
significant change was observed either in the duration of silent period or in the 
shape of silent period regarding the appearance of LEP. Late excitatory potentials 
not only did not show any inclination to diminish after memantine treatment but on 
the contrary their appearance increased. These results support the conclusion 
derived from our main TMS experiment that it is indeed the cholinergic system 
which regulates cortical inhibition in the brain during voluntary muscle contraction.  
In addition, our sub-experiment with memantine provided more evidence to 
our experiment with donepezil regarding the significant difference in the duration 
and morphology of silent period between early AD patients and normal individuals 
of the same age. The 5 untreated patients participating in the sub-experiment with 
memantine displayed the same pattern in their SP as the untreated patients in the 
experiment with donepezil. This added 5 more patients to our initial patient group of 
13 patients thus increasing the statistical value of our results.  
Although based almost solely on our experimental results, we did not 
hesitate to conclude that, at least in the early stages of Alzheimer’s disease, the 
cholinergic system exerts important control upon the inhibitory neuronal circuits of 
the motor cortex. The cholinergic dysfunction which characterizes the early stages of 
Alzheimer’s disease causes a malfunction of the inhibitory neuronal pathways of the 
brain. This provokes a scattering of the silent period by electromyographic 
breakthroughs (LEPs) as a complete cessation of electromyographic activity is 
difficult to sustain. It becomes evident that cortical disinhibition which is caused by a 
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cholinergic deficit results in a silent period fragmented and longer in duration in 
early AD patients when compared to normal individuals of the same age. 
Given the scarcity of previous research on the topic, we carefully reviewed 
the literature for the existence of any scientific evidence addressing, even indirectly, 
the impact of Alzheimer’s disease on the various inhibitory neuronal pathways of the 
brain and the possible role of the related neurotransmitters in the regulation of the 
function of these pathways.  Di Lazarro was the first investigator who experimentally 
proved a close relationship between the cholinergic system and the inhibitory 
mechanisms of the cerebral cortex [84].  He observed, after the intravenous 
administration of scopolamine in normal individuals, a very significant reduction in 
the amount of short-latency afferent inhibition (SAI) evoked by somatosensory input 
from the hand.  Short-latency afferent inhibition is based on coupling electrical 
peripheral nerve stimulation with motor cortex stimulation by TMS.  SAI refers to the 
suppression of the amplitude of a MEP caused by a conditioning afferent electrical 
stimulus upon the median nerve of the wrist of the contralateral hand area. The 
conditioning electrical stimulus is exerted at the median nerve approximately 20 ms 
prior to the application of TMS. Scopolamine is a medication which blocks the 
muscarinic receptors of acetylcholine. Given that short latency afferent inhibition 
(SAI) reflects inhibition in the level of interaction between the sensory and motor 
system of cerebral cortex, this experimental study proved the central role of 
cholinergic system in cortical inhibition. 
After establishing the strong connection between SAI and cholinergic 
function in the normal brain, Di Lazzaro evaluated short-latency afferent inhibition in 
Alzheimer’s disease patients. His experimental study of 2002 [54] revealed that 
Alzheimer’s disease patients had a significantly reduced amount of SAI by 
comparison to normal subjects. After the oral administration of the 
acetylcholinesterase inhibitor rivastigmine, an elevation in SAI was observed.  
Another experiment performed by this group has shown that short-latency afferent 
inhibition is influenced by GABAergic drugs as well. Particularly, when 
benzodiazepine lorazepam was administered in healthy subjects, a significant 
reduction of SAI was induced [85]. Di Lazzaro et al. explained these changes in SAI 
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attributing a central role to acetylcholine in its regulation. [54]. They also proposed 
an involvement of other neurotransmitters, such as glutamate and GABA, in the 
whole process [57]. Despite various assumptions, a certain model of the exact way 
the cholinergic system interacts with neuronal pathways mediated by other 
neurotransmitters in the regulation of cortical inhibition was not proposed by Di 
Lazarro. Nevertheless, his work provided important evidence of a serious 
dysfunction of the inhibitory mechanisms in the level of interaction between sensory 
and motor areas of the brain in patients suffering from Alzheimer’s disease. His work 
also underlined the serious impact of the lack of acetylcholine in the etiology of this 
dysfunction serving as indirect support for our own results concerning impaired 
inhibition in early AD. 
Nardonne, in his experimental study in 2008 [53], confirmed the conclusions 
of Di Lazarro et al. regarding the decreased short-latency afferent inhibition in 
Alzheimer’s disease. More interestingly, he conducted his experiment focused on 
early AD as the patients he recruited were all in the initial stages of the disease. The 
mean amount of SAI was significantly smaller in the group of early AD patients in 
Nardone’s study compared to normal subjects suggesting an early impairment of 
cholinergic function in AD which seriously affects the SAI. More importantly, the 
study of Nardone serves as a very significant argument to our own results of 
decreased cortical inhibition in patients in early AD because of the similar 
methodology. The experimental studies of Di Lazzaro and Nardone assessing SAI 
allow us to conclude that despite the different level of inhibition that silent period 
and short latency afferent inhibition refer to, the former post-synaptically, the latter 
pre-synaptically, we can assume a global dysfunction of the inhibitory mechanisms 
of the cerebral cortex in early AD closely related to cholinergic dysfunction. 
Di Lazarro and Nardone in their TMS studies, apart from assessing the short-
latency afferent inhibition as an indicator of cortical inhibition in the sensorimotor 
level and  a marker of cholinergic function, also assessed short-interval intra-cortical 
inhibition (SICI) in AD patients [54,55,86].  Short-interval cortical inhibition is a 
paired–pulse TMS paradigm [87].  It involves a subthreshold conditioning stimulus 
that precedes a suprathreshold test stimulus adjusted to produce an average MEP of 
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0.5–1.5 mV peak-to-peak amplitude in the contralateral muscle. In order to measure 
short-interval cortical inhibition, conditioning stimuli are applied to the motor cortex 
before the test stimulus at inter-stimulus intervals (ISIs) between 1 ms and 4 ms.  
These investigators presented results showing that SICI was reduced in AD patients 
by comparison to normal individuals. Interestingly, the study of Pepin et al. [50] 
which included more advanced AD patients showed no difference of SICI between 
patients and normal subjects. Taking into account that Narbone performed his TMS 
study with early AD patients as we did in our study, our conclusions about a 
dysfunction of the inhibitory cortical mechanisms in early AD are further supported. 
The results of Nardone and Di Lazzaro about decreased short interval cortical 
inhibition (SICI) in Alzheimer’s disease are in accordance with the much older study 
of Liepert at al. [83]. According to the literature SICI is likely to be mediated by 
GABAergic inhibition at the intra-cortical level [88, 89].  Furthermore, it has been 
proved through experiments with pharmacological agents [90] that short-interval 
cortical inhibition is related to GABA-A receptor–mediated inhibitory 
neurotransmission. Reduced SICI suggests a dysregulation of the intra-cortical 
GABAergic inhibitory circuits. 
Collating all the aforementioned studies with the results of our own study, 
we concluded that indeed there is impairment in various levels of cortical inhibition 
in Alzheimer’s disease from the early stages. The reduction of short-latency afferent 
inhibition (SAI) represents impaired inhibition in the brain areas between the motor 
and sensory system in a presynaptic level and is related to central cholinergic 
activity.  Reduced short interval intracortical inhibition (SICI) suggests a 
dysregulation of the intra-cortical GABAergic inhibitory circuitries with GABA-A 
mediation predominantly involved.  The prolongation of silent period due to its 
fragmentation by the presence of multiple LEP reflects an impaired, long lasting 
cortical inhibition at the postsynaptic level and is mediated predominantly by GABA-
B receptors [91, 92]. 
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4.5. THE CONNECTION BETWEEN DECREASED EXCITABILITY AND 
IMPAIRED INHIBITION OF THE MOTOR CORTEX 
As silent period represents in a dynamic manner cortical inhibition during 
voluntary muscle contraction caused by TMS stimulation of the contralateral motor 
area, our experimental results were indicative of a dysregulation of the mechanisms 
responsible for the muscle contraction in early AD. This dysregulation was attributed 
to a dysfunction of the motor cortex in early AD patients closely related to a 
cholinergic dysfunction. Moreover, by evaluating the active motor threshold of these 
patients we have also shown that a decrease in the excitability of the primary motor 
cortex exists in early AD patients. The decreased cortical excitability was also  closely 
related to a dysfunction of the cholinergic neurons in early AD.  So, a very interesting 
challenge arose: to investigate the existence of a connection between the impaired 
cortical inhibition at the postsynaptic level that the scattered and prolonged silent 
period demonstrated with the reduced excitability of the primary motor area that 
the increased  aMT suggested in early AD. The discovery of such a connection would 
create a model which could convincingly describe the changes that Alzheimer’s 
disease, from the early stages, causes in the function of primary motor during a 
motor action from its initiation to its implementation. Furthermore, it would give a 
clearer view of the neuronal pathways that are involved in the regulation of a motor 
action and the specific neurotransmitters these pathways utilize in their function. 
In our effort to establish this connection we should briefly review the 
physiology of the TMS procedure. The process  starts  with the transynaptical  
activation of the pyramidal cells in primary motor area (M1) by TMS, continues with 
the genesis of the indirect (I) waves which travel through the corticospinal tract 
activating the alpha-motoneurons at the spinal level and is terminated with the 
genesis of a MEP in the tested muscle of the contralateral area. The genesis of the 
MEP represents the muscle contraction as a response to the TMS stimulation. When 
we stimulate the M1 with stimulus intensity of 150 % of the motor threshold while 
the individual performs a voluntary muscle contraction, silent period emerges due to 
CHAPTER  4 - DISCUSSION 
- 60 - 
 
the activation of certain inhibitory mechanisms so as to improve the plasticity of the 
movement. It is widely accepted that SP and MEP are correlated to some extent. The 
question arises though as to the anatomical basis of the relationship between SP and 
MEP. Given that MEP is closely related to threshold reflecting cortical excitability 
while SP represents cortical inhibition in the postsynaptic level, the answer to this 
question would provide us with a fundamental formula to describe the connection 
between the decreased cortical excitability and the impaired cortical inhibition 
observed in early AD. 
It has been well recognized in the past that both SP duration and MEP 
amplitude are linearly related to the intensity of the TMS stimulation [46, 62, 94, 95, 
96].  Orth and Rothwell in their study in 2004 [97] observed that this correlation was 
stably present for all the individuals tested and was independent of the pulse 
waveform of the TMS stimulus. By calculating ratios of silent period duration and the 
corresponding MEP area these investigators managed to reduce the variability 
between subjects and the magnetic stimulator for the current flow direction when 
TMS was applied. This led them to suggest that the factors which were causing 
variation in the MEP were the same as those which caused variation in the duration 
of the silent period. The most probable explanation they provided was that the 
corticospinal outflow that produces the MEP is also responsible for the generation of 
the SP. 
It is already known that TMS primarily activates the fast–conducting 
pyramidal neurons leading to the genesis of MEP. However, from experiments in 
cats [98] it is also known that recurrent collaterals of these fast conducting neurons 
exert an inhibitory effect on slower-conducting pyramidal neurons most probably by 
exciting intercalated inhibitory neurons. As slowly-conducting pyramidal neurons are 
responsible for the maintenance of tonic voluntary muscle contraction, the 
inhibition of those neurons is presumed to be responsible for the occurrence of the 
silent period. The proposed model of Orth and Rothwell, suggesting that the 
occurrence of silent period is in close relation to the genesis of a MEP in the targeted 
muscle during TMS stimulation was later confirmed by other TMS studies [63, 64]. 
This model provided us with the necessary, adequate neurophysiological basis to 
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connect cortical excitability with cortical inhibition. However, in order to form a 
complete picture about the mechanisms of the changes which take place in the 
primary motor cortex of early AD patients, we should expand and support this 
neurophysiological model with knowledge of neuroanatomy about the neuronal 
pathways which lie underneath.  
 
4.6. A PATHOPHYSIOLOGICAL MODEL CONCERNING ALTERED MOTOR 
FUNCTION IN EARLY AD. 
We know from neuroanatomy, further confirmed by animal experiments in 
rats that there is a very rich presence of cholinergic fibers in layer I of the primary 
motor area which lessens significantly in layers II-III [99]. The apical dendrites of 
pyramidal cells (PC) which are rich in cholinergic afferents are located in layers II-III. 
A strong release of ACH from cholinergic axons located in layer I can therefore 
stimulate the apical dendrites of the PC found in layers II-III by acting on their 
muscarinic receptors. However, layers II-III of M1, apart from containing the apical 
dendrites of pyramidal cells, are also very rich in GABAergic neurons [100,101]. From 
the various types of GABAergic neurons located in these layers a specific cell type, 
called basket GABAergic neurons, connects its axons to the apical dendrites of the PC 
of this area forming a common neuronal circuit.  Combining this information from 
the literature we proceeded to form our hypothesis. 
We  suggest that when acetylcholine is released from the cholinergic axons of 
the layer I of M1, it activates not only the apical dendrites of the pyramidal cells  of 
the inferior layers II-III  but also certain GABAergic  neurons of these layers as parts 
of the common neuronal circuit that these GABAergic neurons form with the 
dendrites of the pyramidal cells.  It is well understood and accepted that 
acetylcholine have an excitatory effect on the brain [102] while GABA is the main 
inhibitory neurotransmitter [103,104].  According to the physiological model we 
suggest, it becomes clear that the release of acetylcholine to the M1 leads to the 
activation of the pyramidal cells of the primary motor cortex thus increasing cortical 
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excitability while simultaneously this release activates certain GABAergic neurons of 
this area affecting cortical inhibition. 
After forming our physiological model which illustrates this type of   
interconnection between cortical excitability and cortical inhibition, we reviewed the 
literature for any additional evidence of the effect of excitatory or inhibitory 
neuronal networks upon the pyramidal cells of M1. We found that Xiang at al. [105] 
in an animal experiment with rats, have demonstrated the existence of a selective 
cortical muscarinic disinhibition of the pyramidal cells. Specifically, Xiang’ research 
has shown that acetylcholine hyperpolarizes a certain type of inhibitory 
interneurons, the fast spiking (FS) cells located in layer V of M1 which forms 
functional synapses on layer V pyramidal  cells. As the axons of the FS inhibitory 
interneurones in layer V tend to be distributed more horizontally (intralaminar), 
their hyperpolarization results in disinhibition of their pyramidal cell targets of the 
same area. Thus, the activation of the cortical cholinergic system could reduce some 
forms of intralaminar inhibition. Together with direct muscarinic depolarisation of 
layer V pyramidal cells it could increase pyramid-pyramid recurrent excitation finally 
enhancing cortical excitability. This study outlined the important role of the 
cholinergic system upon the function of pyramidal cells through the regulation of the 
excitatory and inhibitory neuronal network further validating our hypothesis. 
Taking into consideration the physiological model we have suggested 
concerning the interaction between the various cell types in the different layers of 
the primary motor area and given the direct connections that according to recent 
data [69] exist between the basal forebrain and the motor cortex, we applied the 
model of Orth–Rotwell to our experimental results. Therefore, we suggest that the 
disturbance in acetylcholine output observed in early Alzheimer’s disease leads to a 
decrease in the excitability of the fast contacting pyramidal cells (PC) which are 
responsible for the production of MEP during TMS resulting to an increased motor 
threshold. Subsequently, the activation of the intercalated inhibitory GABAergic 
neurons which are directly affected by the firing of PC is also reduced. This results in 
less inhibition exerted by these GABAergic neurons onto the slow-conducting 
pyramidal cells which are responsible for the maintenance of the voluntary isometric 
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muscle contraction. The final outcome of the impaired inhibition on the slow-
conducting PC is the appearance of various LEPs which fragment the valley of the 
silent period and increase its duration. Our study has shown that the oral 
administration of the acetylcholinesterase inhibitor donepezil caused normalization 
both in the active motor threshold and in the shape and duration of SP significantly 
reducing LEPs.  In this way the key role of the cholinergic system becomes apparent 
as a regulating factor in the function of motor cortex in patients of Alzheimer’s 
disease and explains the altered motor behaviour that these patients exhibit from 
the early stages.   
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CHAPTER 5. 
FINAL CONCLUSIONS 
Our study creates an original view of the motor function of patients in the 
early stages of Alzheimer’s disease and proposes an explanation for the responsible 
regulatory mechanisms. Our TMS experiment shows an increase of the active motor 
threshold in early AD patients corresponding to a decreased cortical excitability 
when compared to normal individuals of the same age. It demonstrates a 
differentiation in the function of the primary motor cortex in AD from disease onset. 
This points to the fact that not only are the areas of the brain responsible for 
memory and cognition affected early in the process of the disease but the primary 
motor cortex is involved as well. 
Investigating the mechanisms that are responsible for the decreased 
excitability of motor cortex in early AD patients, we hypothesized a key role of the 
cholinergic system in the regulation of cortical excitability considering the 
significance of the cholinergic hypothesis in the pathogenesis of Alzheimer’s disease. 
The restoration of the active motor threshold to normal after the oral administration 
of the cholinesterase inhibitor donepezil argues in favor of a cholinergic regulation of 
cortical excitability in early AD. The absence of any traceable change in the active 
motor threshold in a group of early AD patients after receiving memantine which 
acts without implicating the cholinergic system reinforced the soundness of our 
initial hypothesis. 
The assessment of the reaction time in early AD patients when given a simple 
visual stimulus confirmed from a different perspective the effect of Alzheimer’s 
disease on the alertness of the motor system. The increased simple reaction time 
and simple movement time that these patients displayed when compared to normal 
patients are in accordance with the decreased excitability of the primary motor 
cortex addressed by our TMS study. A hypo-excitable motor cortex is unable to  
react quickly with a muscle contraction to a given visual stimulus. 
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The ‘normalization’ of reaction time after donepezil intake outlined the crucial role 
of acetylcholine in the ability of the motor cortex to be properly alert in order to 
react with the necessary speed every time that an implementation of a movement is 
required.  
Recent studies have shown that the cholinergic deficit that exists in early AD 
is not caused by a cholinergic neuronal loss in the basal forebrain. A modulation of 
the synaptic cleft associated with a dysfunction of the cholinergic neurons and a loss 
of signaling by the nerve growth factor seems to be implicated. In the light of this 
scientific evidence our initial hypothesis about the functional role of the cholinergic 
system upon motor control in early AD patients became a reasonable argument.  
Thus, we came to the conclusion that the disturbance in acetylcholine output 
in early AD, apart from being one of the main reasons for the deficit in cognitive 
function of the affected individuals, is also responsible for the alteration of their 
motor behaviour. Early Alzheimer’s disease causes a certain cholinergic dysfunction 
in the basal forebrain (BF) which affects the primary motor area (M1) directly 
through a connecting neuronal pathway; recent data reveal the existence of a direct 
connection between BF and M1. This cholinergic dysfunction results in the elevation 
of the active motor threshold manifesting itself in a decreased excitability of the 
primary motor cortex. The decreased excitability of the primary motor area is 
reflected on a clinical level as altered motor behaviour in the form of hypo-
movement for the patients in early AD. 
Observing the form of movement of the AD patients in more progressed 
stages as well, we concluded that the motor behaviour of the AD patients is stage 
dependent.  Given the increased cortical excitability which is evident in advanced 
Alzheimer’s disease, in contrast to the decreased excitability of the early stages, we 
were able to establish a similarity between Alzheimer’s disease and amyotrophic 
lateral sclerosis.  Though very different in pathophysiology, both neurodegenerative 
diseases affect the motor cortex following a pattern of stage dependent changes 
upon cortical excitability in terms of qualitative measures.  The changes in the 
excitability of the motor cortex during the evolution of the neurodegeneration could 
be a common adaptive phenomenon in neurodegenerative diseases.  
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The measurement of the silent period provided a more holistic evaluation of 
the function of motor system in early AD. SP calculation, as an indicator of cortical 
inhibition, added a dynamic view upon physiology of a generated movement beyond 
the sole assessment of cortical excitability that the motor threshold reflects. The 
increase in duration of the silent period in the group of early AD patients was 
attributed to the fragmentation of SP valley by multiple late excitatory potentials 
due to cortical disinhibition. Given that silent period itself is a marker of late motor 
cortical inhibition in the postsynaptic level during voluntary muscle contraction, we 
concluded that an impairment of cortical inhibition is present in the early stages of 
Alzheimer’s disease along with decreased cortical excitability. The restoration of the 
duration and shape of silent period of the early AD patients back to normal values 
after the intake of donepezil outlines the important role of the cholinergic system in 
the regulation of cortical inhibition during muscle contraction. The absence of any 
effect of memantine in the duration and shape of the silent period further reinforced 
the validity of our conclusion that the mechanisms which regulate cortical inhibition 
during early AD are acetylcholine dependent. 
The common denominator between the decreased cortical excitability and 
the impaired cortical inhibition in the early AD patients is a disturbance in cholinergic 
output. Thus, we suggest a functional model which connects cortical excitability 
(aMT) with cortical inhibition (SP) under the regulation of the cholinergic system. 
The scientific work of Orth and Rothwell which argues that the spinal outflow that 
produces the MEP is also responsible for the generation of the SP provided us with a 
sound basis for doing so.  
While TMS primarily activates the fast-conducting pyramidal neurons leading 
to the genesis of MEP, recurrent collaterals stemming from them, through the 
excitation of intercalated inhibitory neurons have an inhibitory effect on the slower-
conducting pyramidal neurons. Given that slow-conducting pyramidal neurons are 
responsible for the maintenance of tonic voluntary muscle contraction, their 
inhibition leads to the occurrence of silent period. Neuroanatomy and animal 
experiments indicate that layer I of M1 is very rich in cholinergic fibers. The apical 
dendrites of pyramidal cells (PC) which are rich in cholinergic afferents are located in 
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layers II–III of M1. Also layers II–III of the motor cortex are very rich in GABAergic 
neurons, a specific type of which (the basket cells) form, via their axons, a 
connecting neuronal network with the apical dendrites of the PC located there. 
We applied all the aforementioned to our experimental results in order to 
present our final proposal. So, we suggest that the disturbance in Acetycholine 
output from the cholinergic axons of layer I of M1 in early AD leads to a decrease in 
the excitability of the fast conducting pyramidal cells (PC) which are responsible for 
the production of MEP. This decreased excitability of the PC is illustrated as 
increased motor threshold. Subsequently, the excitability of the intercalated 
inhibitory GABAergic neurons which are activated by collaterals stemming from the 
fast conducting PC is reduced. Less inhibition is exerted by these GABAergic neurons 
onto the slow-conducting PC which are responsible for the maintenance of the 
voluntary isometric muscle contraction. As the muscle contraction is not 
efficaciously inhibited, various LEPs appear resulting in the fragmentation and 
prolongation of the SP valley being demonstrative of an impaired inhibition at a 
postsynaptic level. Donepezil intake appears to normalize both the active motor 
threshold and the shape and duration of the SP. This illustrates the interconnection 
that exists, according to our functional model, between decreased cortical 
excitability and decreased cortical inhibition in early AD with the cholinergic system 
as the regulating factor. 
The complete model which our study proposes regarding the function of the 
motor cortex in Alzheimer’s disease conforms to neuroanatomy, neurophysiology 
and previous suggestions by Brown and Pluck. It initiates a new way to view the 
motor behaviour of patients suffering by Alzheimer’s disease. The actual changes in 
the motor behaviour of the affected individuals have a strong relationship with the 
existing cognitive deficit caused by AD. Through our study, motor behaviour is 
viewed in close relationship to cognition. A person moves his facial and body parts in 
response to the environmental stimuli based on his cognitive reserve. The motor 
cortex is no longer theorized as an isolated brain area but as a dynamic place; it 
interacts with the associative brain areas and the limbic system in order to generate 
a movement as the final expresser of a complete procedure including cognitive 
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processing. According to our study, the disturbance in the function of the cholinergic 
system is one of the main reasons for the altered motor behaviour of the patients in 
the initial stages of Alzheimer’s disease as similarly it is responsible for the 
impairment of their more purely cognitive functions. 
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